Revisiting the Roles of Filaggrin in Atopic Dermatitis

Verena Moosbrugger-Martinez 1, Corinne Leprince 2, Marie-Claire Méchin 2, Michel Simon 2, Stefan Blunder 1, Robert Gruber 1 and Sandrine Dubrac 1,*

1 Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria; verena.martinz@i-med.ac.at (V.M.-M.); stefan.blunder@i-med.ac.at (S.B.); robert.gruber@tirol-kliniken.at (R.G.)
2 Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Toulouse University, CNRS UMR5051, Inserm UMR1291, UPS, 31059 Toulouse, France; corinne.leprince@inserm.fr (C.L.); marie-claire.mechin@inserm.fr (M.-C.M.); michel.simon@inserm.fr (M.S.)

* Correspondence: sandrine.dubrac@i-med.ac.at; Tel.: +43-512-504-23025

Abstract: The discovery in 2006 that loss-of-function mutations in the filaggrin gene (FLG) cause ichthyosis vulgaris and can predispose to atopic dermatitis (AD) galvanized the dermatology research community and shed new light on a skin protein that was first identified in 1981. However, although outstanding work has uncovered several key functions of filaggrin in epidermal homeostasis, a comprehensive understanding of how filaggrin deficiency contributes to AD is still incomplete, including details of the upstream factors that lead to the reduced amounts of filaggrin, regardless of genotype. In this review, we re-evaluate data focusing on the roles of filaggrin in the epidermis, as well as in AD. Filaggrin is important for alignment of keratin intermediate filaments, control of keratinocyte shape, and maintenance of epidermal texture via production of water-retaining molecules. Moreover, filaggrin deficiency leads to cellular abnormalities in keratinocytes and induces subtle epidermal barrier impairment that is sufficient enough to facilitate the ingress of certain exogenous molecules into the epidermis. However, although FLG null mutations regulate skin moisture in non-lesional AD skin, filaggrin deficiency per se does not lead to the neutralization of skin surface pH or to excessive transepidermal water loss in atopic skin. Separating facts from chaff regarding the functions of filaggrin in the epidermis is necessary for the design efficacious therapies to treat dry and atopic skin.

Keywords: atopic dermatitis; filaggrin; epidermis; NMF; pH; microbiome

1. Filaggrin: A Look in the Rear-View Mirror

Filaggrin was initially isolated from a protein fraction of the stratum corneum (SC) and identified as a basic histidine-rich protein [1]. Proteins from this fraction were shown to aggregate with keratin filaments to form macrofibrils in vitro cell-free experiments [2]. In 1981, Dale et al. designated this class of cationic structural proteins, which associate specifically with intermediate filaments but not with other types of cytoskeletal proteins, as filaggrins (for filament aggregating proteins) [2]. They showed that filaggrins are species-distinct proteins; for example, rat and mouse filaggrins have different molecular weights (48 and 30 kDa, respectively) and different amino acid totals but nevertheless exhibit similar chemical and functional properties. The ability of filaggrin to aggregate keratin filaments into tight parallel arrays [3] has been demonstrated in many different experimental settings, with high reproducibility [4–7]. This molecular bundling confers mechanical resilience and flexibility to the SC [8]. Mouse and human filaggrin bind to each three-chain building block of the intermediate filaments, possibly through ionic interactions with the coiled-coil alpha-helical regions of the keratin filaments. The stoichiometry of the interaction has been reported as two filaggrin molecules to three intermediate (keratin) filament subunits [3,9].

Further work demonstrated that filaggrin is produced as a phosphorylated precursor, profilaggrin, of 300–500 kDa, depending on the species [10–12], embedded in keratohyalin
granules in granular keratinocytes (KCs) \[2,13,14\]. Subsequently, profilaggrin undergoes a multiple-step dephosphorylation process, followed by proteolytic cleavage of short linker peptides to produce various numbers of filaggrin monomers depending on the species, e.g., 10 to 12 in humans, 16 to 20 in mice \[15–17\], and only 4 in dogs \[18\]. Profilaggrin is present in the stratum granulosum (SG), whereas filaggrin monomers are localized in the first layers of the SC. Of note, there is often confusion between profilaggrin and filaggrin, with some authors incorrectly assigning filaggrin to the SG. Filaggrin, together with other proteins of keratohyalin granules, forms the protein moiety of the cornified cell envelope of corneocytes \[19–23\]. In rat corneocytes, filaggrin was found to represent about 10% of the cell envelope-bound proteins \[24\]. Early work suggested the involvement of one or more specific phosphatases in filaggrin dephosphorylation \[11,25\], and in 1988, a rat 40 kDa phosphatase specific for profilaggrin was isolated \[26\] and later characterized as a protein phosphatase 2A-type \[25\]. However, data concerning specific profilaggrin phosphatases in humans are scant.

In 1993, calpain 1 was proposed as a profilaggrin protease because profilaggrin cleavage requires calcium, and calpains are calcium-dependent neutral proteases \[27\]. In 2009, processing of human profilaggrin by human calpain 1 was confirmed in a cell-free proteolytic assay \[28\]. Moreover, cathepsin L-like proteinase, but not cathepsin E, isolated from rat epidermis was shown to hydrolyze profilaggrin \[29\]. Work in mice showed that loss of cathepsin H, produced by an shRNA approach, leads to a dramatic reduction of filaggrin monomers, owing to defective profilaggrin processing in the epidermis \[30\]. The results for cathepsin D are contradictory, and the enzyme is likely not essential for profilaggrin processing in vivo \[29,31,32\]. Furthermore, profilaggrin endoproteinase 1 (PEP1) has been identified as a cytoplasmic enzyme that is able to digest insoluble profilaggrin purified from mouse epidermis, at least in proteolytic assays \[33\]. In addition, both furin and PACE4, two calcium-dependent serine proteases belonging to the same family of proprotein convertases, can cleave profilaggrin in vitro at a site between the amino terminus and the first filaggrin repeat \[34\]. In mice, genetic deletion of matriptase/MT-SP1, a type II transmembrane serine protease expressed in epithelial cells, including KCs, leads to failure to process profilaggrin into filaggrin monomers \[35\]. Moreover, it has been shown that skin-specific retroviral-like aspartic protease (SASPase) activity is indispensable for processing profilaggrin in mouse epidermis \[36\], a requirement which may extend to human epidermis \[37,38\]. SASPase cleaves the linker sequence of human profilaggrin between ‘GSFLY’ and ‘QVSTH’ \[36\]. Moreover, it has been proposed that lympho-epithelial Kazal type inhibitor (LEKTI), a protease inhibitor encoded by the SPINK5 gene, controls profilaggrin proteolysis. Indeed, SPINK5 knockout mice or mice with a premature stop codon in SPINK5—both are mouse models of Netherton syndrome, a severe ichthyosis due to null mutations in SPINK5—display increased amounts of mature filaggrin and reduced amounts of profilaggrin, indicating that proteolytic processing of profilaggrin is enhanced \[39,40\]. In human KCs, it was further shown that mesotrypsin liberates a 55-kDa N-terminal fragment of profilaggrin, hence potentially contributing to filaggrin processing as well \[41\]. Lastly, in transgenic mice overexpressing elastase 2, the rate of profilaggrin processing into filaggrin monomers is accelerated. In line with this, in the SG of patients with Netherton syndrome, elastase 2 is upregulated and co-localizes with profilaggrin, and profilaggrin levels are reduced \[42–44\]. Thus, many different proteases have been shown to potentially cleave profilaggrin into filaggrin monomers.

In the upper SC, filaggrin is further processed by various proteases into free amino acids. The proteolysis of filaggrin is enhanced by its prior deamination or by citrullination. The latter is a post-translational modification catalyzed by peptidylarginine deiminase enzymes, resulting in the conversion of arginine into citrulline, thereby reducing its charge (citrulline is a neutral residue, whereas arginine is positively charged) and promoting detachment of the filaggrin monomer from the aggregated keratins \[45–47\]. Histidine and glutamine are then either enzymatically or spontaneously transformed to trans-urocanic acid (UCA) and pyrrolidone carboxylic acid (PCA), respectively. These amino acids and
derivatives are components of the natural moisturizing factor (NMF), together with other molecules, such as lactate, chloride and sodium ions, and urea, thus ensuring proper SC hydration [48]. Interestingly, studies with histidinemic or caspase-14-deficient mice or with epidermal equivalents knocked-down for FLG have shown a role for trans-UCA in the protection of skin against the damaging effects of UV-B radiation [5,49–54].

In 1986, Scott and Harding established that proteolysis of filaggrin in rat skin is controlled by atmospheric humidity. Filaggrin is first detected at day 20 of rat gestation in all layers of the neo-formed SC. A few hours after birth, filaggrin disappears from the upper SC layers and accumulates in the innermost half of the SC, before being confined to a thin layer at the bottom of the SC, two days after birth. In addition, keeping the newborn rat in 100% humidity or applying occlusive patches onto the skin of adult rats prevents the activation of filaggrin degradation. The authors concluded that the lowering of atmospheric humidity promotes filaggrin proteolysis into water-retaining molecules [55]. This was confirmed first in mice [56] and then in humans, using 3D epidermal equivalents [57]. Indeed, when human epidermis is produced ex vivo at low atmospheric humidity, as compared to the typical saturated conditions, profilaggrin synthesis is increased, as is filaggrin degradation into UCA and PCA. This is in line with measurements conducted in humans, showing that NMF levels are low at birth and increase within hours or days after birth in healthy baby skin [58]. These results suggest that changes in the skin microenvironment, as occurs at birth, activate filaggrin degradation but not necessarily via increased protease activity. Indeed, it has been shown in vitro that reducing the external humidity increases filaggrin deimination and, as a consequence, the molecule’s dissociation from the filamentous corneocyte matrix [46,47,57,59]. This may render filaggrin more accessible to proteases [48]. Moreover, these results suggest that improper bundling of filaggrin with keratin filaments might promote filaggrin degradation in the absence of other alterations, such as increased activity of proteases. Besides external humidity, the neutral cysteine protease bleomycin hydrolase has been shown to participate in the breakdown of deiminated filaggrin into amino acids in a cell-free proteolytic assay [28]. Moreover, bleomycin hydrolase-deficient mice display reduced amounts of skin NMF and higher levels of filaggrin [60]. Furthermore, in healthy baby skin, regional upregulation of bleomycin hydrolase activity, e.g., in the cheek when compared to the elbow flexure, might contribute to increased skin hydration at specific body sites [58].

Thus, SASPase and calpain 1 might play important roles in the processing of profilaggrin into filaggrin, whereas bleomycin hydrolase and caspase 14 are probably major proteinases responsible for filaggrin breakdown in the skin (Table 1, Figure 1); however, the contribution of other proteinases cannot be ruled out.

Table 1. Summary of enzymes and enzyme inhibitors involved in filaggrin metabolism (sometimes still hypothetic) in the epidermis according to data generated in vitro and in animal models versus in humans.
2. The Impact of the FLG Gene: From Ichthyosis Vulgaris to Atopic Dermatitis

Ichthyosis vulgaris (IV) is a common skin disorder in humans, characterized by dry, rough, and scaly skin. In 1985, it was first reported that keratohyalin granules, profilaggrin, and filaggrin are all reduced or absent in the epidermis of patients with IV and that these biochemical abnormalities correlate with the clinical severity of the disease [61]. In 1991, high-resolution ultrastructural immunolabeling showed many small filagrin-positive granules in association with bundles of keratin filaments in IV SG [20]. However, unequivocally, the amounts of filaggrin are much lower in the SC of IV patients compared to that of healthy volunteers [20]. In 2006, genetic studies shed new light on the IV disorder, with the identification of loss-of-function mutations in the FLG gene associated with moderate or severe IV [62]. In the same year, Palmer et al. showed that FLG loss-of-function mutations are strongly associated with atopic dermatitis (AD) [63], suggesting that low amounts of filaggrin in AD might result from genetic causes. Indeed, earlier pioneering reports showed a decrease of filaggrin in lesional AD epidermis [64], regardless of skin lesion presence or absence [65,66]. AD, also known as atopic eczema, is the most common inflammatory skin diseases, affecting 1%–36% of children and up to 18% of adults, of whom approximately 20% have moderate-to-severe disease [67–70]. Here it is important to emphasize that reduced filaggrin levels are also observed in AD patients who are genotypically the wild type for FLG [65,71], demonstrating that FLG variants are not the only factors responsible for filaggrin downregulation in AD skin, and that other
factors (e.g., environmental, metabolic) are also likely to be involved. Moreover, African American patients with AD exhibit normal levels of filaggrin, in contrast to Asian and European patients [66,71]. On the other hand, pediatric AD, regardless of the patient’s ethnic background, might be characterized by normal skin levels of filaggrin [72]; however, most studies lack either FLG genotyping or measurements of filaggrin amounts [64,72–74].

The half-life of rodent filaggrin in the SC is 6–9 h, demonstrating that filaggrin degradation is a relatively rapid process [16,75]. This high turnover of filaggrin may confer vulnerability to the epidermis because factors that lead to reduced filaggrin expression or that accelerate its degradation could have rapid effects on the biological processes in which filaggrin is involved. Conversely, environmental factors or therapies able to augment filaggrin expression might have rapid beneficial effects. Thus, it is important to decipher accurately all the physiological roles of filaggrin in the epidermis so that pathways potentially ameliorable by filaggrin-targeted therapy are fully identified.

3. FLG Null Mutations Are Strong Genetic Factors in AD

The strong association between FLG null mutations and AD (OR = 13.4), first observed by Palmer et al. [63], was subsequently confirmed by many other research groups in studies of various ethnic populations [76–102]. The strength of this association was initially reported to depend on FLG genotype; that is, in a cohort of 186 patients with AD, homozygosis for the combined null genotype of six major null mutations (R501X, 2282del4, R2447X, S3247X, 3702delG, and 3673delC) was more strongly associated with the disease (OR = 85.9) compared to heterozygosis (OR = 4.6) [103]. Furthermore, Brown et al. found, in a large cohort of children, that heterozygosis is not significantly associated with AD (OR = 1.2), as opposed to homozygosis (OR = 26.9) [104]. Nomura and Kabashima suggest that the initial overestimation of the strength of the association of FLG null mutations with AD, especially in heterozygous patients, is likely due to recruitment of patients with severe disease symptoms [67]. Nevertheless, it remains that FLG homozygosis or compound heterozygosis significantly increases the risk of developing AD, at least in adult European and Asian populations [71,105]. However, Morar et al. found FLG null mutations in 26.7% of young patients with AD, but also in 14.4% of children without AD [106]. Subsequent studies have confirmed that about 40%–50% of all carriers of FLG null alleles never experience eczema [107,108]. Thus, these data show strong but incomplete penetrance of FLG variants [63,80,109–111], whose impact on AD development might be modulated by ethnic-specific genetic modifiers, epigenetic alterations, or other environmental factors.

Beyond FLG mutations, the number of filaggrin monomers encoded by an FLG allele can vary from 10 to 12 in humans. Individuals with 20 copies of the filaggrin monomer (i.e., homozygous 10/10) were reported to have an increased risk of developing AD, whereas those with 21 to 24 copies (genotypes 10/11 to 12/12) had no significantly elevated risk, at least in patients with moderate AD [112]. Similar work in patients with low-to-mild AD would give additional information on the power of the association between the different numbers of filaggrin monomers (i.e., genotypes) and the disease expression.

FLG null mutations have been shown to correlate with AD severity and persistence in adulthood [77,88,106,113,114]. Indeed, the observed higher prevalence of adult AD patients with an FLG null mutation (42%) [113] when compared to pediatric patients (13%) [104] argues for a role of FLG status in disease evolution, although this remains to be confirmed in large patient cohorts with different ethnic backgrounds.

A new classification of AD patients according to age, ethnicity, concomitant atopy, inflammatory milieu, SC lipid abnormalities, and FLG status designated as ‘endotypes’ has recently been proposed. In this perspective, AD patients with FLG null mutations represent a particular endotype [66,115].

4. Decreased Filaggrin in Atopic Skin, Regardless of FLG Genotype

The relationship between FLG genotype and amounts of filaggrin in the epidermis is not a direct one, at least in AD. Howell et al. showed that filaggrin mRNA and protein levels
are reduced in both non-lesional and lesional AD skin, regardless of FLG genotype [116]; this is a finding confirmed by others [65,117,118]. However, FLG heterozygosis further decreases filaggrin mRNA and protein amounts in acute skin lesions [116]. Thus, in AD skin lesions, FLG heterozygosis and the micromilieu might synergize to further diminish filaggrin amounts [116]. However, there may be differences between acute and chronic AD lesions, with a stronger reduction of profilaggrin compared to filaggrin in acute lesions and conversely in chronic lesions [65]. These differences likely result from modulation of profilaggrin or filaggrin processing by microenvironmental factors, because FLG mRNA levels are similar in acute and chronic lesions [119]. It has been hypothesized that immunological factors, notably Th2 cytokines, are responsible for modulation of filaggrin in AD skin. Indeed, KCs or human skin equivalents treated with various cytokines, i.e., IL-13, IL-4, IL-25, and thymic stromal lymphopoietin (TSLP) alone or in combination at doses ranging from 50 to 100 ng/mL, display reduced levels of filaggrin mRNA and protein [65,116,120,121]. Similar results have been found after treatment with IL-22, IL-17A, or IL-31 in the same dose range [122–125]; in contrast, IL-33 exerts only minor effects [126]. Data on IFN-γ are contradictory, even though all three IFN-γ studies utilized the same amount of cytokine, i.e., 20 ng/mL [116,120]. Thus, it is now well accepted that Th2 cytokines downregulate filaggrin. However, it must be emphasized that AD epidermis contains much lower levels of cytokines, i.e., in the picogram range in both human and mouse AD skin [127–129]. Therefore, the use of lower amounts of cytokines in vitro experiments might better mimic the physiopathological skin microenvironment, including a potential synergistic effect of cytokines.

Various studies in AD patients provide several hints about the effect of the skin cytokine milieu on filaggrin expression. FLG expression is normalized in AD patients treated with cyclosporine, concomitant with reductions in the expression of Th2, Th17, and Th22, which are key cytokines in the skin [130]. Moreover, FLG expression is also normalized in AD patients treated with Dupilumab, a monoclonal antibody that inhibits IL-4 and IL-13 signaling by binding to their receptors. This effect is associated with the downregulation of the expression of IL17A, IL23, and IL22, as well as the upregulation of several other cytokine genes, including IL5, IL31, and IL33 [130,131]. The filaggrin mRNA level is further increased in the skin of high responders to Dupilumab treatment, in which IL4, IL17, IL22, IL23A, and IL31 are all downregulated [130]. However, whereas Th2 inflammation is observed in all AD endotypes, filaggrin downregulation is endotype-specific [66], suggesting a marginal role of Th2 cytokines per se. Furthermore, an overarching role of Th22/Th17 inflammation is also not compatible with the modulation of filaggrin expression observed in the different AD endotypes [66]. Thus, it is likely that the inflammatory skin milieu alone is not sufficient to downregulate (directly or indirectly) filaggrin in AD patients who are genotypically the wild type for FLG. Other factors might significantly affect filaggrin expression in AD skin, as well. For example, the hypothesis of accelerated filaggrin proteolysis in AD, as mentioned above, has yet to be explored.

The emphasis given to cytokines as the main effectors of filaggrin abnormalities in AD has practically sidelined thorough study of other potential regulators. Interestingly, sphingosyl-phosphorylcholine, which is upregulated in both lesional and non-lesional AD SC [132], has been shown to downregulate FLG mRNA levels in human KCs, presumably via upregulation of intracellular reactive oxygen species (ROS), NADPH oxidase 5, and cyclooxygenase-2 [133], suggesting that lipid abnormalities in AD might regulate filaggrin. In addition, mice with epidermal deletion of the SIRT1 gene, encoding the Sirtuin1 protein, a lysine deacetylase, develop AD-like symptoms associated with nearly complete absence of profilaggrin and filaggrin [134]. In line with this, lesional AD skin displays low levels of Sirtuin1 [134]. However, the molecular mechanisms involved in sirtuin regulation of filaggrin expression are not clear [134]. Other pathways might dampen FLG expression in AD skin, such as the involvement of transcription factors (e.g., aryl hydrocarbon receptor gene (AHR), API, POU, and hypoxia-inducible factor (HIF)1/2α) that are known to bind the FLG gene promoter region; however, further work is required. Interestingly, mTOR/RAPTOR
can downregulate FLG via attenuation of the AKT1 pathway [30]. Moreover, AKT1 has been shown to stabilize the binding of actin to profilaggrin in keratohyalin granules [135], potentially decreasing the hydrolysis of profilaggrin into monomers. This may be clinically important because AKT1 is markedly reduced in the skin of AD patients [30]. Interestingly, preliminary work on human KCs showed that epigenetic modifications, e.g., DNA methylation at the 5′-end of the FLG gene, might also modulate FLG expression [136,137], and DNA hypermethylation in the FLG promoter has been evidenced in lesional AD skin when compared to non-lesional AD skin [137]. However, in the latter study, the authors did not correlate the levels of DNA methylation and the expression of FLG in lesional versus non-lesional AD skin. Thus, additional regulators of FLG expression in AD, beyond the immunological microenvironment, deserve greater scrutiny.

The inflammatory microenvironment, skin dryness and/or dysbiosis, and/or abnormalities in the cytoskeleton might lead to de-coordination between FLG expression and filaggrin amounts in AD [36,138,139]. Pellerin et al. showed that, although the amounts of profilaggrin and filaggrin are both decreased in non-lesional and lesional skin of adult AD patients, regardless of FLG genotype, filaggrin is reduced more than profilaggrin [65,140]. This observation suggests that either (1) the activity of the proteases, which cleave profilaggrin into filaggrin monomers, is decreased or (2) the degradation of filaggrin into its breakdown products is increased in AD. The reduced amounts of activated caspase 14 and cathepsins and the reduced activity of bleomycin hydrolase observed in AD skin, irrespective of lesions [120,140–142], favor the first hypothesis (Figure 2). Of note, the rapamycin-insensitive complex mTOR2/AKT reduces profilaggrin processing into filaggrin in mouse epidermis, potentially via decreased mRNA levels of cathepsin H [143]. However, the role of mTOR2 in AD remains elusive [144].

![Diagram of Control of profilaggrin and filaggrin processing in atopic dermatitis: summary of data collected in mouse models and patients with atopic dermatitis](image_url)

**Figure 2.** Control of profilaggrin and filaggrin processing in atopic dermatitis: summary of data collected in mouse models and patients with atopic dermatitis. Changes in protein amounts in atopic skin is shown by using a color code (orange, increase; green, decrease). Enzymes written in bold show regulation consistent with modulation of amounts of profilaggrin and filaggrin observed in atopic skin [30,120,140,141,145–148]. * Only studied in mice. PEP1, profilaggrin endoproteinase 1; LEKTI, lympho-epithelial Kazal-type-related inhibitor; MT-SP1, matriptase; UCA, urocanic acid; PCA, pyrrolidone carboxylic acid.

Altogether, these data suggest that reduced levels of filaggrin in atopic skin, in addition to reductions caused by FLG nonsense mutations, might result from inhibition of signaling pathways in response to metabolic changes, inflammation, skin dysbiosis, or genetic polymorphisms, among other drivers. Moreover, the skin microenvironment might also control the level of methylation of FLG and, in turn, contribute to its downregula-
Altogether, these data suggest that reduced levels of filaggrin in atopic skin, in addition to reduced profilaggrin processing, might result from reduced profilaggrin processing rather than from accelerated filaggrin degradation (Figure 2). Further studies are needed to identify the upstream signals responsible for profilaggrin catabolism in AD skin.

Figure 3. Summary of filaggrin regulation and roles in atopic dermatitis: experimentally confirmed roles (darkest boxes, white writing) versus prevailing ideas, most of them unsubstantiated. Decreased parameters are in green boxes, and increased parameters are in orange boxes.

5. Filaggrin Deficiency Induces Subtle Epidermal Barrier Impairment in Non-Lesional AD

Several studies conducted in mice support a role of FLG loss-of-function mutations in causing SC leakiness to environmental molecules, i.e., in lessening the outside-in barrier. The first reports were carried out in flaky tail mice, which exhibit a frameshift mutation in Flg, leading to the synthesis of a truncated profilaggrin. These mice show increased paracellular permeability barrier of the SC to hydrophilic molecules—water-soluble molecules are normally not able to penetrate the SC due to its high lipid content [149–151]. Unfortunately, flaky tail mice also carry a spontaneous mutation in the Transmembrane Protein 79/Matt gene (Tmem79) and exhibit AD-like dermatitis, which precludes conclusions on the role of filaggrin based on this model. Thus, to circumvent off-target effects due to this additional mutation and to skin inflammation, Flg knockout mice have been utilized. Topical application of various molecules (unmodified or liposome-encapsulated) onto the skin of Flg knockout mice demonstrated increased SC permeability [6]. Moreover, topical application of either croton oil, hapten, or ovalbumin onto the skin of these mice resulted in increased skin inflammation, edema, and serum IgE [6], suggesting an altered outside-in barrier able to induce local and systemic inflammation. However, mouse epidermis, including the SC, is much thinner than human epidermis, leaving unanswered the real capacity of FLG null mutations to increase the permeability of human SC. Nevertheless, in biopsies from IV patients, lanthanum nitrate has been shown to progress via paracellular pathways into and across the SC, whereas there is no such movement in the skin of healthy volunteers [7]. Furthermore, FLG homozygous compound heterozygous IV patients exhibit altered cornodesmosome structure and abnormal topography of the corneocyte surface [7,60]. Moreover, morphological changes of corneocytes and of cornodesmosomes have been observed in IV, likely resulting from retraction of keratin bundles and abnormal
lamellar body secretion, respectively [7,152]. Previous work showed that kallikrein 7, a serine-protease able to cleave corneodesmosin [153], is upregulated in FLG knockdown human epidermal equivalents and the skin of AD patients [154,155]. Thus, filaggrin deficiency might alter corneocyte and corneodesmosome morphology enough to increase the permeability of the human SC to environmental compounds (outside-in barrier). However, further work is required to validate this hypothesis. Indeed, FLG null mutations do not increase the diffusivity of PEG 370 through the non-lesional skin of AD patients [156]. Furthermore, in FLG knockdown full-skin organotypic models, there were no changes in the flux of a lipophilic model compound, butyl-PABA, through the SC, clearly demonstrating that filaggrin deficiency does not affect SC permeability to this molecule [157]. These data highlight the difficulty in verifying the hypothesis of increased SC leakiness in the context of filaggrin deficiency and in performing functional assays with human skin. Indeed, a proper analysis of SC permeability requires multiple assays, including permeability and diffusion studies (e.g., Franz cell chamber) and experimental models [158].

Flg knockout mice do not exhibit increased transepidermal water loss (TEWL) [6]. This is in line with unaltered SC lipid organization, lateral packing, and content (ceramides; free fatty acids, including (very)-long-chain fatty acids; cholesterol) observed in FLG knockdown full-skin organotypic models [154] and in Flg knockout mice [156]. Accordingly, FLG knockdown does not alter the expression of enzymes involved in free fatty acid elongation, such as Elongation of very-long chain fatty acids (ELOVL)1, 4, and 6; and of stearoyl-CoA desaturase 1, β-glucocerebrosidase, and α-sphingomyelinase in both epidermal equivalents [125] and mouse skin [159]. Furthermore, the absence of epidermal tight junction morphological changes and leakiness in Flg knockout mice demonstrate that filaggrin deficiency has no deleterious effect on the paracellular barrier in living epidermal layers [160]. Thus, filaggrin deficiency per se does not alter the epidermal inside-out barrier [152,161].

In the context of AD, FLG null mutations have little or no impact on the epidermal barrier healing process, as evidenced by the lack of effects on SC barrier recovery after tape stripping or after skin irritation [162,163]. Moreover, as emphasized by Jung and Stingl, overt morphological and functional defects in the epidermal barrier in AD are independent of FLG null mutations [164,165]. In line with this, TEWL in non-lesional AD skin is similar between FLG-mutated patients and FLG wild-type patients [156,162,166–169], suggesting no additional impairment of the epidermal barrier in AD skin due to FLG loss-of-function mutations [170]. These results are corroborated by similar relative compositions and amounts of SC ceramides—a profile which directly correlates with epidermal barrier efficacy [171–173]—in non-lesional skin of FLG-mutated and FLG wild-type AD patients [162,167].

Thus, filaggrin deficiency, regardless of genotype, contributes to an abnormal lamellar body cargo system and secretion and alters corneocyte morphology, resilience, and surface properties by acting on keratin organization and cornified envelopes. Moreover, filaggrin deficiency alters the ultrastructure of corneodesmosomes, as well as the SC lipid matrix (i.e., disorganized lamellar bilayers with incompletely processed lamellar material and lacunae). All of these subtle abnormalities of the SC might favor the penetration by specific but not all molecules according to their physicochemical properties.

6. Filaggrin Deficiency Promotes Subclinical Inflammation in the Epidermis Nonspecific to AD

Proteomic analysis of FLG knockdown in human epidermal equivalents showed increased amounts of inflammation-related proteins, albeit with only weak or indirect links to specific inflammatory processes [153]. In contrast, FLG knockdown in human differentiated KCs was shown to augment the production of various cytokines involved in barrier repair, including IL-1α, GM-CSF, IL-8, and IL-18 [174]. However, in epidermal equivalents generated with primary KCs from IV patients, the expression of cytokines involved in barrier repair and AD-specific inflammation was not increased [152]. Discrepancies between the phenotypes of FLG knockdown and primary IV KCs might be due to temporal effects,
i.e. gene knockdown is a relatively quick process during which cells do not have time to compensate the protein loss, in contrast to the situation in patient cells [161,175,176].

TSLP has been shown to be increased in skin lesions of AD patients and to play an important role in AD pathogenesis via activation of Langerhans cells, at least in mouse models [177–181]. Wallmeyer et al. found that FLG knockdown in human full-skin organotypic models results in increased TSLP [182]. However, other work carried out in epidermal equivalents generated with IV patient KCs did not show increased TSLP expression [152], similar to Flg knockout mice [183], suggesting a lack of significant effects of filaggrin deficiency per se on TSLP expression [184]. In AD patients with FLG null mutations, Langerhans cell maturation is promoted, a complex process potentially including reduced amounts of UCA [185]. Thus, filaggrin deficiency in vivo might lead to subclinical skin inflammation via Langerhans cell activation rather than via upregulation of pro-inflammatory cytokines in KCs.

Work undertaken in mice showed that filaggrin deficiency promotes AD-like symptoms in mice with a BALB/c background [183], in contrast to mice with a C57BL/6 background [186], showing that (1) filaggrin is a permissive but not an eliciting factor; and (2) other acquired factors, including immunological susceptibility, are important in AD pathogenesis. Indeed, filaggrin deficiency might promote a Th17 immune response [187–189] that can be found not only in AD but also in other inflammatory skin diseases (e.g., psoriasis and ichthyoses). Interestingly, filaggrin is expressed in the mouse thymic medulla [190], suggesting further systemic immunomodulatory effects of filaggrin deficiency. In line with this, proportions of circulating Th2- or Th17-regulatory T cells (Tregs) are increased in AD and accentuated by FLG null mutations. Moreover, FLG null mutations are associated with expansion of thymus-emigrated Tregs in AD [188].

Thus, filaggrin deficiency does not trigger inflammatory pathways specific to AD but might contribute to Th17 inflammation via regulation of T-cell priming in the thymus and to Langerhans cell activation via, inter alia, reduced levels of UCA, whose role in immunological reactions in the skin deserves further investigation [191]. However, most work has been carried out in mice or in vitro and warrants validation in patients.

7. Does Filaggrin Deficiency in Atopic Skin Lead to Alkalization of the Skin?

Free fatty acids, components of the NMF (including UCA), and the Na/H proton pump all are believed to contribute to the establishment of an acidic skin surface pH, thereby limiting the overgrowth of microbes [192] and controlling desquamation through protease activity. Thus, filaggrin is believed to contribute to surface-skin pH acidification via its degradation into UCA. The first evidence of a role for UCA in skin-surface pH was published in 2000 [193]. To experimentally identify the main biologic components involved in the acidity of the SC, the authors placed a drop of water in contact with the skin for 30 min to collect proton donors. Then, using a mathematical extrapolation model, they showed a significant contribution of UCA to surface-skin acidification [193]. However, the use of water as a solvent prevents the collection of water-insoluble proton donors, such as fatty acids, whose pKa can be similar to or even higher than that of UCA (e.g., pKa stearic acid = 10.15 versus pKa UCA = 6.1) [193,194]. Of note, the ratio of free fatty acids to UCA is about 6–7 in human epidermis. Thus, any significant contribution of UCA to acidification of the skin surface can be questioned. Moreover, several studies suggest that filaggrin deficiency does not significantly alter surface-skin pH. Flg knockout mice do not display significant changes in surface-skin pH [6]. Moreover, studies in IV patients showed either unchanged [163] or slightly increased skin-surface pH but still within the acidic range (<6) [7,142,170,195]. In contrast, it has been observed that a decreased amount of UCA parallels an increased surface pH in human epidermal equivalents knocked-down for filaggrin 2, in which profilaggrin processing is impaired and there is a reduced amount of filaggrin [196].

Thus, the role of filaggrin in acidification of the skin surface via the production of UCA can still be debated [197]. As a corollary, increased protease activity in lesional AD
skin [198,199] is an unlikely outcome of filaggrin deficiency. It is more likely that filaggrin breakdown-products significantly contribute to water retention and skin osmolarity, and thereby to SC flexibility [60]. Moreover, it is often forgotten that skin bacteria can use histidine as a substrate and be a significant local source of UCA [200].

8. Effects of Filaggrin Deficiency on the Skin Microbiota in AD

Several lines of evidence suggest a role for filaggrin deficiency in controlling the composition of the skin microbiota. Filaggrin-deficient individuals, regardless of AD, harbor an altered bacterial skin microbiota, with reduced proportions of Gram-positive bacteria, namely Finegoldia (Finegoldia magna), Anaerococcus, and Peptoniphilus, which are all capable of using histidine as a nutrient (carbon) source. This might be a consequence of nutrient competition driven by the loss of histidine-rich filaggrin [195]. However, Finegoldia magna utilizes amino acids such as glycine, serine, and threonine as major energy sources [201,202], and Anaerococcus and Peptoniphilus primarily use peptone [203]. Because filaggrin is rich in glycine (13.6% of total amino acids) and serine (25.3%), the reduced proportions of Gram-positive bacteria on the skin of filaggrin-deficient individuals might also be related to reduced levels of glycine and serine in the SC.

Frequent microbial skin infection in AD patients seems unlikely to result simply from the observed small shift in surface-skin pH, which remains in the acidic range in AD patients, including in severe skin lesions, regardless of FLG genotype (see below). However, filaggrin deficiency, irrespective of genetic or environmental origins, might contribute to skin dysbiosis and its various clinical manifestations by reducing the levels of UCA and PCA, substances which have been shown to exert antimicrobial properties [189]. Indirect evidence comes from work on caspase-14-deficient mice, which showed impaired clearance of Escherichia coli after topical challenge [204]. These results suggest a role for filaggrin breakdown products in the clearance of skin pathogens.

FLG null mutations have been associated with modification of the microbiota more in non-lesional AD skin than in lesional AD skin [205], notably by decreasing the relative abundance of Proteobacteria and increasing that of Actinobacteria [206]. Moreover, there is an inverse correlation between Staphylococcus aureus and Cutinobacterium acnes in AD skin [207], suggesting that these bacteria are competitors or that the skin microenvironment favoring the growth of one of these bacterial species is strongly unfavorable to the growth of the other [207]. Accordingly, in IV and AD patients without Staphylococcus aureus, the amount of Cutinobacterium acnes is increased when compared to healthy controls [208]. Moreover, the amount of Cutinobacterium acnes is increased in FLG-mutated AD patients when compared to FLG wild-type AD patients [208], suggesting that physicochemical changes to the skin microenvironment induced by filaggrin deficiency might promote the growth of Cutinobacterium acnes. However, no associations have been found between acne and FLG null mutations [209]. Thus, FLG null mutations might favor the growth of Cutinobacterium acnes to an extent that allows bacterial competition but not to a level that provokes acne (i.e., dysbiosis, not infection).

FLG status might modulate the skin fungal microbiota in AD, as IV patients exhibit fungal dysbiosis [208] and increased fungal skin infections [210]. However, little work has been carried out in this direction so far. A pilot study showed that FLG null mutations are modifiers of the fungal microbiota in AD, notably by leading to enrichment in Cladosporium and Malassezia, especially Malassezia globosa, and to diminution of Debaryomyces and Leptosphaeria [208]. Thus, FLG null mutations might accentuate fungal dysbiosis in AD, which might steepen Th17 immunity [187–189].

FLG null mutations confer increased risk to eczema herperticum (OR = 3.4) in both European and African ancestry populations [211]. However, the role of filaggrin deficiency in susceptibility to viral infection in AD patients remains almost uninvestigated.
9. Filaggrin Deficiency per se Does Not Promote Colonization of Atopic Skin with *Staphylococcus aureus*

A recent pilot study found that, while patients with IV display increased proportions of staphylococcal species on their skin, *Staphylococcus aureus* is not detected [208]. Absence of *Staphylococcus aureus* was also reported in an earlier study of IV [195]. Thus, initial evidence does not support a strong association between filaggrin deficiency per se and skin colonization with *Staphylococcus aureus*; however, further work in larger IV patient cohorts is required.

In the context of AD, the data concerning the status of *Staphylococcus aureus* lack clarity. Recent work has shown that, in lesional AD skin, *Staphylococcus aureus* [212,213] and especially the CC1 clonal lineage [212] are more prevalent in FLG-mutated than in FLG wild-type AD patients. The type of genetic polymorphism (nonsense vs. missense) in FLG might be important for colonization of the skin by this bacterium in AD [213]. Conversely, Indian patients with moderate-to-severe AD and a higher number of loss-of-function FLG alleles display a lower abundance of *Staphylococcus aureus* [214]. Moreover, in a German cohort of AD patients with moderate-to-severe AD, no specific enrichment of the skin microbiota with *Staphylococcus aureus* was found in FLG-mutated patients [206], similar to findings in Danish and Austrian cohorts with mainly low-to-moderate AD [205,208].

A current hypothesis states that the increased skin-surface pH observed in AD is a consequence of reduced NMF levels (due to reduced filaggrin proteolysis or FLG haploinsufficiency), which, in turn, favors skin superinfection with *Staphylococcus aureus* [215]. It is assumed that the bacterial superinfection then damages the epidermal barrier and elicits an immune response in KCs. However, this hypothesis is challenged by several observations. First, *Staphylococcus aureus* is present in skin lesions of AD patients with moderate-to-severe AD, whereas it is rare or absent in AD patients with low-to-mild symptoms, regardless of FLG status [195,205–208,216–218]. Second, skin-surface pH is not consistently increased in AD, but when it is increased, it remains in the acidic range (≤6), including in AD skin lesions and regardless of FLG status [142,167,215,219,220]. Moreover, *Staphylococcus aureus* can proliferate over a pH range from 5 to 9, with no major disruption to growth between pH 5.5 and 7.0 [221]. Thus, the minor variation of skin-surface pH observed in AD cannot explain *Staphylococcus aureus* overgrowth [206]. Third, filaggrin does not play a major role in the establishment of acidic skin-surface pH, as already discussed above. Of additional note, although several studies in vitro have shown that staphylococcal enterotoxin B (SEB), lipoteichoic acid, or various proteases secreted by *Staphylococcus aureus* are able to damage the epidermal barrier and induce an immune response in KCs [222], in vitro treatment of KCs or organotypic cultures with these molecules is only a partial experimental approach to the situation in vivo.

Van Drongelen et al. showed that, in FLG knockdown human epidermal equivalents infected with *Staphylococcus aureus*, the proportions of adherent bacteria are increased, suggesting that filaggrin deficiency might promote the attachment of the bacteria to the SC. The authors extrapolated, in the context of AD, that FLG null mutations might promote skin superinfection via this mechanism [125]. Because patients with IV exhibit skin dysbiosis toward increased staphylococci and specifically toward increased *Staphylococcus epidermidis*, whereas *Staphylococcus aureus* is absent in the skin of these patients [208], it would be interesting to repeat the experiments of Van Drongelen et al. with *Staphylococcus epidermidis*. Although previous work has shown that filaggrin deficiency does not increase the risk of skin superinfection with *Staphylococcus aureus* in AD [206,208,223], it still might be an aggravating factor. In 1986, *Staphylococcus aureus* toxin was shown to bind to filaggrin [224], suggesting that the absence or strong reduction of filaggrin might facilitate alteration of the epidermis by preventing the retention of the staphylococcal toxin within the SC. Moreover, filaggrin might protect KCs from the toxicity of staphylococcal α-toxin by secreting sphingomyelinase [225].

Thus, filaggrin deficiency per se might not promote colonization of atopic skin with *Staphylococcus aureus* and, a fortiori, not via increased skin surface pH (as discussed above).
It is more likely that an attenuated innate immunity, owing to impairment of the epidermal barrier [226], lifts the growth inhibition on *Staphylococcus aureus* in lesional AD. However, in superinfected skin, filaggrin deficiency might favor *Staphylococcus aureus* binding to the SC [224] and enhance the deleterious effects of staphylococcal toxin on the SC [227,228]. Interestingly, low levels of NMF strengthen *Staphylococcus aureus* binding to corneocytes via an interaction between the bacterial adhesion clumping factor B (ClfB) and corneocyte surface ligands or the N-terminal region of cornodesmosin [227,228].

10. Filaggrin Deficiency Leads to Cellular Abnormalities in Keratinocytes: Potential Relevance in AD

In AD, *FLG* null mutations worsen the cellular and molecular abnormalities in KCs [142]. Microarray analysis of skin initially showed that several pathways, such as focal adhesion, ECM receptor interaction, and regulation of the actin cytoskeleton, are more altered in *FLG*-mutated than in *FLG* wild-type AD patients [142]. Moreover, other cellular features, such as the phosphatidylinositol signaling system, calcium signaling, T-cell receptor signaling, ABC transporters, and tight junctions, are significantly altered only in *FLG*-mutated AD patients when compared to wild types [142]. Analysis of the crystal structure of specific domains of human profilaggrin demonstrated that it might bind to three proteins, namely annexin II/p36, stratifin/14-3-3 sigma, and heat shock protein 27 [229], which are involved in cell motility, linkage of membrane-associated protein complexes to the actin cytoskeleton, endocytosis/exocytosis, ion channel formation, cell matrix interactions, KC differentiation, and apoptosis. Thus, it would be interesting to see whether these interactions do take place in KCs and whether filaggrin deficiency could affect processes controlled by these binding partners.

In 1997, Dale et al. transiently transfected rodent epithelial cells with constructs encoding one-to-five human filaggrin monomers and observed cell contraction, nuclear membrane breakdown, and nuclear condensation, which are hallmarks of cell apoptosis. They proposed that filaggrin might be involved in KC death in the upper SG [4]. However, in 2000, the same group reported that inducible overexpression of mature filaggrin in KC cell lines did not increase cell death. Nonetheless, they showed that filaggrin-positive cells were more susceptible to cell death after treatment with UV-B or hydrogen peroxide [230]. The authors speculated that KC apoptosis at the transition zone between the SG and SC, which is a process requiring oxidative stress, might be facilitated by filaggrin [230,231].

The amino-terminal sequence of profilaggrin exhibits significant homology to the so-called small calcium-binding proteins such as S100 [232]. Because the S100 domain can bind calcium, profilaggrin has been proposed to play an important role in KC differentiation, potentially via activation of calcium-dependent protein kinase C (PKC) [232], which has been shown to induce KC differentiation [233]. It was shown that the N-terminal AB fragment of profilaggrin comprising the S100 domain and a nuclear localization signal can be translocated into the nucleus of KCs [41,234], and its accumulation there induces DNA degradation and cell death [41], diminishes cell proliferation, and alters differentiation [234]. Mesotrypsin liberates a 55 kDa N-terminal fragment of profilaggrin able to migrate into the KC nucleus [41]. Similarly, caspase 14 increases the production of the filaggrin AB fragment, hence potentially contributing to KC death [41]. Thus, several pieces of evidence show that cleavage of profilaggrin in granular transient KCs might release a protein fragment that is able to migrate into the nucleus and contribute to cell death. Thus, profilaggrin processing might significantly participate in the cornification process. However, it should be noted that IV patients exhibit degenerating nuclei in granular KCs, suggesting an impaired process of nucleophagy potentially leading to premature cell death [62]. Several lines of evidence suggest that, in AD and IV, absence or reduced amounts of profilaggrin might impair proper KC terminal differentiation rather than contribute to KC hyperproliferation [152,157,229,235].

Thus, in AD, low amounts of profilaggrin (not filaggrin) might alter the cornification process in KCs. This might also perturb cell metabolism, potentially inducing premature cell death via nucleus degeneration, thereby preventing the proper expression of other
proteins of the cornified envelope such as hornerin, involucrin, and loricrin [236,237]. However, further work is required to validate or dismiss this hypothesis.

11. FLG Null Mutations Regulate Skin Moisture in Non-Lesional AD

Heterozygosity for FLG null mutations augments the risk of dry skin in both women and men (OR = 2.7–7.4) [238,239], and wild-type individuals with 10 filaggrin repeats (10/10 genotype) have drier skin (self-perceived) than those with 12 repeats (12/12 genotype) [240], including in AD [166,241]. The amount of NMF is reduced in ichthyotic individuals carrying FLG null mutations [168,242–244] and in FLG-mutated AD patients [241]. In AD skin, the concentrations of filaggrin breakdown products correlate with FLG copy number, with UCA having a greater correlation than histidine or PCA [112]. Work in mice suggests that low levels of NMF resulting from filaggrin deficiency confer stiffness to corneocytes [60], and this might ultimately lead to reduced skin elasticity and promote itch. However, recent work by Ota et al. showed that the development of skin inflammation during the transition between non-lesional to lesional AD correlates with reduced levels of filaggrin breakdown products, regardless of FLG null mutations [245].

Observations in IV patients demonstrate that FLG null mutations induce dry skin, indicating that the amount of filaggrin in the skin is a determinant of proper skin moistness. In non-lesional AD, FLG null mutations leading to reduced filaggrin result in dry skin, whereas non-lesional AD skin from FLG wild-type patients does not exhibit xerosis. In contrast, in lesional AD, the skin is dry in all AD patients, irrespective of FLG null mutations, showing that other factors, such as metabolic, inflammatory, and/or microbial microenvironments, supersede the FLG genotype.

12. FLG Null Mutations Are Less Penetrant Genetic Factors in the Atopic March than in AD

The atopic march describes the progression across time of AD to allergic rhinoconjunctivitis and asthma. However, this evolution does not affect all AD patients. Indeed, it mainly depends on disease severity, since about 70% of patients with severe AD develop asthma versus 20%–30% of patients with mild AD. Similar observations have been made for allergic rhinoconjunctivitis, whose risk in AD patients correlates with the levels of total and specific IgE antibodies [246]. Initial work by Palmer et al. showed that FLG null mutations are significantly associated with asthma (OR = 1.8), although to a much lesser extent than with AD (OR = 13.4) [63], thus suggesting a role for FLG null mutations in the atopic march [247–250]. Indeed, it is now clear that FLG null mutations are associated with asthma only in the context of AD [251–253], because this association is lost in large patient cohorts of all ages without AD [104,254]. Moreover, the resolution of atopic symptoms in elderly individuals, despite FLG null mutations [114,255], suggests that the immune system overrides any genetic predisposition with regard to atopy.

Filaggrin is strongly expressed in the cornified epithelium of the nasal vestibular lining, but not in the transitional and respiratory nasal epithelia, which might explain why FLG null mutations are a risk factor for allergic rhinoconjunctivitis (OR = 2.64, penetrance 15.4%) [251]. Weidinger et al., the authors of that study, suggest that it is unlikely that FLG null mutations exert organ-specific and local effects in the upper airways; rather, they privilege a mechanism through which the mutations might contribute to increased percutaneous priming and, in turn, to the induction of Th2 inflammation in nasal epithelium [251].

The higher levels of serum IgE in AD patients with FLG null mutations initially suggested a role for filaggrin in allergic sensitization [77,106]. Subsequently, this association was confirmed in several studies [251,253,256–260]. The hypothesis is that filaggrin deficiency renders the SC more permeable to environmental allergens. In line with this, a strong association between FLG null mutations and sensitization to grass, house dust mites, cat dander, and other allergens has been evidenced in various ethnic populations [107,166,261]. In two independent cohorts, a significant interaction between FLG loss-of-function mutations and cat (but not dog) ownership at birth on the development of early-life eczema
has been demonstrated [262]. Moreover, AD patients with FLG null mutations display increased blood Derp1+ CD4+ T cells (Derp1 is a house dust mite allergen), hence providing molecular immunological evidence of a link between FLG null mutations and systemic T-cell reactivity to allergens [263].

Increased susceptibility to peanut allergy has been consistently found in FLG carriers (OR = 3.0–5.4), suggesting increased sensitization via SC leakiness, as traces of peanuts were found in dust deposited on a lounge-sofa [235, 258, 264–266]. Interestingly, in a recent study, Berdyshev et al. showed that lower levels of filaggrin breakdown products, namely UCA and PCA, correlate with peanut allergy, irrespective of AD [267], suggesting that inflammation is not involved in the increased permeability of the skin to peanut allergens. Unfortunately, the authors did not genotype the study participants, hence precluding a potential association with FLG genotype. Thus, the relationship between FLG null mutations and food allergies deserves further work [268, 269].

A controversy over the association between allergic dermatitis and FLG null mutations exists [239, 265, 269–274]. For example, there is no association between latex allergy and FLG null mutations [275, 276]. Moreover, an allergen avoidance strategy as a measure of prevention both during pregnancy and after childbirth yielded disappointing results in AD patients, regardless of FLG status [269].

An association between FLG null mutations and allergic contact dermatitis to nickel (OR = 1.74–4.04) has been consistently observed in several studies [272, 277–281]. Moreover, FLG null mutations seem to lower the age of first appearance of nickel allergy and the threshold to nickel reaction [279]. Interestingly, filaggrin can strongly bind to nickel in the human epidermis [282]. In addition, filaggrin was shown to be susceptible to nickel-assisted peptide bond hydrolysis, hence generating abnormal filaggrin fragments [283]. These results suggest that the binding of nickel to filaggrin in the SC might retain nickel and prevent its further progress into the epidermis to elicit an allergic reaction. Thus, in this context, reduced filaggrin might favor skin sensitization by rendering the SC more permeable to nickel. An exciting question is whether filaggrin might exert similar retention properties for other allergens, especially where the structures of specific allergens are compatible with strong binding to filaggrin. It is noteworthy that filaggrin has been shown to bind to several proteins (https://varsome.com/gene/FLG, first accessed on 13 April 2022).

13. Conclusions

Since the discovery of the strong association between FLG null mutations and AD fifteen years ago, the role of filaggrin in AD pathogenesis has been extensively investigated [284, 285]. It is now well established that profilaggrin and filaggrin have at least three critical roles in KCs: (1) alignment of keratin intermediate filaments; (2) control of cell shape; and (3) maintenance of epidermal texture via production of water-retaining molecules, namely UCA and PCA (Figure 3). Moreover, there is strong evidence that UCA is also involved in protection against solar radiation. Furthermore, filaggrin deficiency alters the ultrastructure of corneocytes and the SC lipid bilayer to facilitate the ingress of exogenous molecules, depending on their physicochemical properties, into living epidermal layers. The capacity of filaggrin to bind foreign molecules, including allergens and bacterial toxins and, in turn, prevent their penetration into the skin deserves further investigation, as does the role of filaggrin in the cornification process by promoting granular KC death at the SG–SC transition. However, the contribution of FLG null mutations to surface-skin pH and to excessive TEWL in AD is probably marginal. Finally, sifting the wheat from the chaff with regard to filaggrin functions in skin homeostasis and in AD pathogenesis will not only advance current basic knowledge in dermatology but will also help deliver reliable data to the skin research community, as such data are indispensable to the design of effective therapies for patients with FLG null mutations.
Author Contributions: Writing—original draft preparation, V.M.-M., C.L., M.-C.M., M.S., S.B., R.G. and S.D.; writing—review and editing, S.D.; literature research, C.L., M.-C.M., M.S. and S.D.; funding acquisition, S.D. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by grants from the Austrian Science Fund and the Tyrol Research Fund (FWF 31662) to S.D.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

AD atopic dermatitis
AHR aryl hydrocarbon receptor
AKT1 RAC(Rho family)-alpha serine/threonine-protein kinase
ELOVL elongation of very-long-chain fatty acids
FLG Filaggrin
GATA3 GATA binding protein 3
GM-CSF granulocyte macrophage colony-stimulating factor
Ig immunoglobulin
IV ichthyosis vulgaris
KC keratinocyte
LEKTI lympho-epithelial Kazal type inhibitor
MAPK mitogen-activated protein kinase
mTOR mammalian target of rapamycin
NMF natural moisturizing factor
OR odds ratio
OVOL1 ovo-like transcriptional repressor 1
PCA pyrrolidone carboxylic acid
PEP1 proFLG endoproteinase 1
PPAR peroxisome proliferator-activated receptor
RAPTOR regulatory-associated protein of mTOR
ROS reactive oxygen species
SC stratum corneum
SASPase skin aspartic acid protease
SG stratum granulosum
TEWL transepidermal water loss
TSLP thymic stromal lymphopoietin
UCA trans-urocanic acid
UV ultraviolet

References

1. Dale, B.A.; Lonsdale-Eccles, J.D.; Holbrook, K.A. Stratum corneum basic protein: An interfilamentous matrix protein of epidermal keratin. Curr. Probl. Dermatol. 1980, 10, 311–325. [PubMed]

2. Dale, B.A.; Vadlamudi, B.; DeLap, L.W.; Bernstein, I.A. Similarities between stratum corneum basic protein and histidine-rich protein II from newborn rat epidermis. Biochim. Biophys. Acta 1981, 668, 98–106. [CrossRef]

3. Mack, J.W.; Steven, A.C.; Steinert, P.M. The mechanism of interaction of filaggrin with intermediate filaments. The ionic zipper hypothesis. J. Mol. Biol. 1993, 232, 50–66. [CrossRef] [PubMed]

4. Dale, B.A.; Presland, R.B.; Lewis, S.P.; Underwood, R.A.; Fleckman, P. Transient expression of epidermal filaggrin in cultured cells causes collapse of intermediate filament networks with alteration of cell shape and nuclear integrity. J. Investig. Dermatol. 1997, 108, 179–187. [CrossRef] [PubMed]

5. Pendaries, V.; Malaisse, J.; Pellerin, L.; Le Lamer, M.; Nachat, R.; Kezic, S.; Schmitt, A.M.; Paul, C.; Poumay, Y.; Serre, G.; et al. Knockdown of filaggrin in a three-dimensional reconstructed human epidermis impairs keratinocyte differentiation. J. Investig. Dermatol. 2014, 134, 2938–2946. [CrossRef]
1. Kawasaki, H.; Nagao, K.; Kubo, A.; Hata, T.; Shimizu, A.; Mizuno, H.; Yamada, T.; Amagai, M. Altered stratum corneum barrier and enhanced percutaneous immune responses in filaggrin-null mice. *J. Allergy Clin. Immunol.* **2012**, *129*, 1538–1546. [CrossRef]

2. Gruber, R.; Elias, P.M.; Crumrine, D.; Lin, T.K.; Brandner, J.M.; Hachem, J.P.; Presland, R.B.; Fleckman, P.; Janecke, A.R.; Sandilands, A.; et al. Filaggrin genotype in ichthyosis vulgaris predicts abnormalities in epidermal structure and function. *Am. J. Pathol.* **2011**, *178*, 2252–2263. [CrossRef]

3. McAleer, M.A.; Irvine, A.D. The multifunctional role of filaggrin in allergic skin disease. *J. Allergy Clin. Immunol.* **2013**, *131*, 280–291. [CrossRef]

4. Steinert, P.M.; Cantieri, J.S.; Teller, D.C.; Lonsdale-Eccles, J.D.; Dale, B.A. Characterization of a class of cationic proteins that specifically interact with intermediate filaments. *Proc. Natl. Acad. Sci. USA* **1981**, *78*, 4097–4101. [CrossRef]

5. Ramsden, M.; Loehren, D.; Balmain, A. Identification of a rapidly labelled 350K histidine-rich protein in neonatal mouse epidermis. *Differentiation* **1983**, *23*, 243–249. [CrossRef]

6. Lonsdale-Eccles, J.D.; Tellier, D.C.; Dale, B.A. Characterization of a phosphorylated form of the intermediate filament-aggregating protein filaggrin. *Biochemistry* **1982**, *21*, 5940–5948. [CrossRef]

7. Meek, R.L.; Lonsdale-Eccles, J.D.; Dale, B.A. Epidermal filaggrin is synthesized on a large messenger ribonucleic acid as a high-molecular-weight precursor. *Biochemistry* **1983**, *22*, 4867–4871. [CrossRef]

8. McAleer, M.A.; Irvine, A.D. The multifunctional role of filaggrin in allergic skin disease. *J. Investig. Dermatol.* **2019**, *139*, 1372–1378. [CrossRef] [PubMed]

9. Steinert, P.M.; Marekov, L.N. The proteins elafin, filaggrin, keratin intermediate filaments, loricrin, and small proline-rich proteins and 1 and 2 are isodipeptide cross-linked components of the human epidermal cornified cell envelope. *J. Biol. Chem.* **1995**, *270*, 17702–17711. [CrossRef] [PubMed]

10. Kawasaki, H.; Nagao, K.; Kubo, A.; Hata, T.; Shimizu, A.; Mizuno, H.; Yamada, T.; Amagai, M. Altered stratum corneum barrier and enhanced percutaneous immune responses in filaggrin-null mice. *J. Allergy Clin. Immunol.* **2012**, *129*, 1538–1546. [CrossRef]

11. Lonsdale-Eccles, J.D.; Teller, D.C.; Dale, B.A. Characterization of a phosphorylated form of the intermediate filament-aggregating protein filaggrin. *Biochemistry* **1982**, *21*, 5940–5948. [CrossRef]

12. Meek, R.L.; Lonsdale-Eccles, J.D.; Dale, B.A. Epidermal filaggrin is synthesized on a large messenger ribonucleic acid as a high-molecular-weight precursor. *Biochemistry* **1983**, *22*, 4867–4871. [CrossRef]

13. Lonsdale-Eccles, J.D.; Haugen, J.A.; Dale, B.A. A phosphorylated keratohyalin-derived precursor of epidermal stratum corneum basic protein. *J. Biol. Chem.* **1980**, *255*, 2235–2238. [CrossRef]

14. Kuechle, M.K.; Thuilin, C.D.; Presland, R.B.; Dale, B.A. Profilaggrin requires both linker and filaggrin peptide sequences to form granules: Implications for profilaggrin processing in vivo. *J. Investig. Dermatol.* **1999**, *112*, 843–852. [CrossRef]

15. Sandilands, A.; Sutherland, C.; Irvine, A.D.; McLean, W.H. Filaggrin in the frontline: Role in skin barrier function and disease. *J. Cell Sci.* **2009**, *122*, 1285–1294. [CrossRef]

16. Resing, K.A.; Walsh, K.A.; Dale, B.A. Identification of two intermediates during processing of profilaggrin to filaggrin in neonatal mouse epidermis. *J. Cell Biol.* **1994**, *99*, 1372–1378. [CrossRef]

17. Gan, S.Q.; McBride, O.W.; Idler, W.W.; Markova, N.; Steinert, P.M. Organization, structure, and polymorphisms of the human profilaggrin gene. *Biochemistry* **1990**, *29*, 9432–9440. [CrossRef]

18. Combarros, D.; Cadiergues, M.C.; Simon, M. Update on canine filaggrin: A review. *Vet. Q.* **2019**, *40*, 162–168. [CrossRef]

19. Steinert, P.M.; Marekov, L.N. The proteins elafin, filaggrin, keratin intermediate filaments, loricrin, and small proline-rich proteins 1 and 2 are isodipeptide cross-linked components of the human epidermal cornified cell envelope. *J. Biol. Chem.* **1995**, *270*, 17702–17711. [CrossRef]

20. Manabe, M.; Sanchez, M.; Sun, T.T.; Dale, B.A. Interaction of filaggrin with keratin filaments during advanced stages of normal human epidermal differentiation and in ichthyosis vulgaris. *Differentiation* **1991**, *48*, 43–50. [CrossRef]

21. Simon, M.; Sebbag, M.; Haftek, M.; Vincent, C.; Girbal-Neuhauser, E.; Rakotoarivony, J.; Sommé, G.; Schmitt, D.; Serre, G. Monoclonal antibodies to human epidermal filaggrin, some not recognizing profilaggrin. *J. Investig. Dermatol.* **1995**, *105*, 432–437. [CrossRef]

22. Simon, M.; Haftek, M.; Sebbag, M.; Montézin, M.; Girbal-Neuhauser, E.; Schmitt, D.; Serre, G. Evidence that filaggrin is a component of cornified cell envelopes in human planar epidermis. *Biochem. J.* **1996**, *317*, 173–177. [CrossRef]

23. Albérola, G.; Schröder, J.M.; Froment, C.; Simon, M. The Amino-Terminal Part of Human FLG2 Is a Component of Cornified Envelopes. *J. Investig. Dermatol.* **2019**, *139*, 1395–1397. [CrossRef]

24. Richards, S.; Scott, I.R.; Harding, C.R.; Liddell, J.E.; Powell, G.M.; Curtis, C.G. Evidence for filaggrin as a component of the cell envelope of the newborn rat. *Biochem. J.* **1988**, *253*, 153–160. [CrossRef]

25. Kam, E.; Resing, K.A.; Lim, S.K.; Dale, B.A. Identification of rat epidermal profilaggrin phosphatase as a member of the protein phosphatase 2A family. *J. Cell Sci.* **1993**, *106*, 219–226. [CrossRef]

26. Haugen-Sофield, J.; Resing, K.A.; Dale, B.A. Characterization of an epidermal phosphatase specific for filaggrin phosphorylated by casein kinase II. *J. Investig. Dermatol.* **2007**, *265*, 553–559. [CrossRef]

27. Resing, K.A.; al-Alawi, N.; Blomqvist, C.; Fleckman, P.; Dale, B.A. Independent regulation of two cytoplasmic processing stages of the intermediate filament-associated protein filaggrin and role of Ca2+ in the second stage. *J. Biol. Chem.* **1993**, *268*, 25139–25145. [CrossRef]

28. Kamata, Y.; Taniguchi, A.; Yamamoto, M.; Nomura, J.; Ishihara, K.; Takahara, H.; Hibino, T.; Takeda, A. Neutral cysteine protease bleomycin hydrolase is essential for the breakdown of denaturated filaggrin into amino acids. *J. Biol. Chem.* **2009**, *284*, 12829–12836. [CrossRef] [PubMed]

29. Kawada, A.; Harai, K.; Hiruma, M.; Noguchi, H.; Ishibashi, A. Rat epidermal cathepsin L-like proteinase: Purification and some hydrolytic properties toward filaggrin and synthetic substrates. *J. Biochem.* **1995**, *118*, 332–337. [CrossRef] [PubMed]

30. Naeem, A.S.; Tommasi, C.; Cole, C.; Brown, S.J.; Zhu, Y.; Way, B.; Willis Owen, S.A.; Moffatt, M.; Cookson, W.O.; Harper, J.I.; et al. A mechanistic target of rapamycin complex 1/2 (mTORC1)/V-Akt murine thymoma viral oncogene homolog 1 (AKT1)/cathepsin H axis controls filaggrin expression and processing in skin, a novel mechanism for skin barrier disruption in patients with atopic dermatitis. *J. Allergy Clin. Immunol.* **2017**, *139*, 1228–1241. [PubMed]

31. Kashima, M.; Fukuyama, K.; Kikuchi, M.; Epstein, W.L. Limited proteolysis of high molecular weight histidine-rich protein of rat epidermis by epidermal proteinases. *J. Investig. Dermatol.* **1988**, *90*, 829–833. [CrossRef]
32. Egberts, F.; Heinrich, M.; Jensen, J.M.; Winoto-Morbach, S.; Pfeiffer, S.; Wickel, M.; Schunck, M.; Steude, J.; Saftig, P.; Proksch, E.; et al. Cathepsin D is involved in the regulation of transglutaminase 1 and epidermal differentiation. J. Cell Sci. 2004, 117, 2295–2307. [CrossRef]

33. Resing, K.A.; Thulin, C.; Whiting, K.; al-Alawi, N.; Mostad, S. Characterization of profilaggrin endoproteinase 1. A regulated cytoplasmic endoproteinase of epidermis. J. Biol. Chem. 1995, 270, 28193–28198. [CrossRef]

34. Pearton, D.J.; Nirunsuksiri, W.; Rehemtulla, A.; Lewis, S.P.; Presland, R.B.; Dale, B.A. Proprotein convertase expression and localization in epidermis: Evidence for multiple roles and substrates. Exp. Dermatol. 2001, 10, 193–203. [CrossRef]

35. List, K.; Szabo, R.; Wertz, P.W.; Sgre, J.; Haedenschild, C.C.; Kim, S.Y.; Bugge, T.H. Loss of proteolytically processed filaggrin caused by epidermal deletion of Matriptase/MT-SP1. J. Cell Biol. 2003, 163, 901–910. [CrossRef]

36. Matsui, T.; Miyamoto, K.; Kubo, A.; Kawasaki, H.; Ebihara, T.; Hata, K.; Tanahashi, S.; Ichinose, S.; Imoto, I.; Inazawa, J.; et al. SASPase regulates stratum corneum hydration through profilaggrin-to-filaggrin processing. EMBO Mol. Med. 2011, 3, 320–333. [CrossRef]

37. Donovan, M.; Salamito, M.; Thomas-Collignon, A.; Simonetti, L.; Desbouis, S.; Rain, J.C.; Formstecher, E.; Bernard, D. Filaggrin and filaggrin 2 processing are linked together through skin aspartic acid protease activation. PLoS ONE 2020, 15, e0232679. [CrossRef]

38. Bernard, D.; Méhul, B.; Thomas-Collignon, A.; Delattre, C.; Donovan, M.; Schmidt, R. Identification and characterization of a novel retroviral-like aspartic protease specifically expressed in human epidermis. J. Investig. Dermatol. 2005, 125, 278–287. [CrossRef]

39. Descargues, P.; Deraison, C.; Bonnart, C.; Kreft, M.; Kishibe, M.; Ishida-Yamamoto, A.; Elias, P.; Barrandon, Y.; Zambruno, G.; Sonnenberg, A.; et al. Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity. Nat. Genet. 2005, 37, 56–65. [CrossRef]

40. Hewett, D.R.; Simons, A.L.; Mangan, N.E.; Jolin, H.E.; Green, S.M.; Fallon, P.G.; McKenzie, A.N. Lethal, neonatal ichthyosis with increased proteolytic processing of filaggrin in a mouse model of Netherton syndrome. Hum. Mol. Genet. 2005, 14, 335–346. [CrossRef]

41. Yamamoto-Tanaka, M.; Makino, T.; Motoyama, A.; Miyai, M.; Tsuboi, R.; Hibino, T. Multiple pathways are involved in DNA degradation during keratinocyte terminal differentiation. Cell Death. Dis. 2014, 5, e1181. [CrossRef] [PubMed]

42. Bonnart, C.; Deraison, C.; Lacroix, M.; Uchida, Y.; Besson, C.; Robin, A.; Briot, A.; Gonthier, M.; Lamant, L.; Dubus, P.; et al. Elastase 2 is expressed in human and mouse epidermis and impairs skin barrier function in Netherton syndrome through filaggrin and lipid misprocessing. J. Clin. Investig. 2010, 120, 871–882. [CrossRef] [PubMed]

43. Furio, L.; Hovnanian, A. Netherton syndrome: Defective kallikrein inhibition in the skin leads to skin inflammation and allergy. Biol. Chem. 2014, 395, 945–958. [CrossRef] [PubMed]

44. Barbieux, C.; Bonnet du Clastres, M.; Fahrner, M.; Petrova, E.; Tsoi, L.C.; Gouin, O.; Leturcq, F.; Nicaise-Roland, P.; Bole, C.; Béziau, V.; et al. Netherton syndrome subtypes share IL-17/IL-36 signature with distinct IFN-α and allergic responses. J. Allergy Clin. Immunol. 2022, 149, 1358–1372. [CrossRef] [PubMed]

45. Méchin, M.C.; Cau, L.; Galliano, M.F.; Daunes-Marion, S.; Poigny, S.; Vidaluc, J.L.; Bessou-Touya, S.; Takahara, H.; Serre, G.; Duplan, H.; et al. Acetyline activates filaggrin degradation by peptidylarginine deiminases in the upper epidermis. J. Dermatol. Sci. 2016, 81, 101–106. [CrossRef] [PubMed]

46. Méchin, M.C.; Takahara, H.; Simon, M. Deimination and Peptidylarginine Deiminases in Skin Physiology and Diseases. Int. J. Mol. Sci. 2020, 21, 566. [CrossRef]

47. Briot, J.; Simon, M.; Méchin, M.C. Deimination, Intermediate Filaments and Associated Proteins. Int J. Mol. Sci. 2020, 21, 8746. [CrossRef]

48. Rawlings, A.V.; Harding, C.R. Moisturization and skin barrier function. Dermatol. Ther. 2004, 17 (Suppl. 1), 43–48. [CrossRef]

49. Barresi, C.; Stremitzer, C.; Mitlz, V.; Kezic, S.; Kammeyer, A.; Ghannad, M.; Posa-Markaryan, K.; Selden, C.; Tschachler, E.; Eckhart, L. Increased sensitivity of histidinemic mice to UVB radiation suggests a crucial role of endogenous urocanic acid in photoprotection. J. Investig. Dermatol. 2011, 131, 188–194. [CrossRef]

50. Denecker, G.; Hoste, E.; Gilbert, B.; Hochezpied, T.; Ovaere, P.; Lippens, S.; Van den Broecke, C.; Van Damme, P.; D’Herde, K.; Hachem, J.P.; et al. Caspase-14 protects against epidermal UVB photodamage and water loss. Nat. Cell Biol. 2004, 6, 666–674. [CrossRef]

51. Gibbs, N.K.; Tye, J.; Norval, M. Recent advances in urocanic acid photochemistry, photobiology and photoimmunology. Photochem. Photobiol. Sci. 2008, 7, 655–667. [CrossRef]

52. Mildner, M.; Jin, J.; Eckhart, L.; Kezic, S.; Gruber, F.; Barresi, C.; Stremitzer, C.; Buchberger, M.; Mitlz, V.; Ballaun, C.; et al. Knockdown of filaggrin impairs diffusion barrier function and increases UV sensitivity in a human skin model. J. Investig. Dermatol. 2010, 130, 2286–2294. [CrossRef]

53. Hoste, E.; Kemperman, P.; Devos, M.; Denecker, G.; Kezic, S.; Yau, N.; Gilbert, B.; Lippens, S.; De Groote, P.; Roelant, R.; et al. Caspase-14 is required for filaggrin degradation to natural moisturizing factors in the skin. J. Investig. Dermatol. 2011, 131, 2233–2241. [CrossRef]

54. Devos, M.; Prawitt, J.; Staumont-Salle, D.; Hoste, E.; Fleury, S.; Bouche, E.; Gilbert, B.; Lippens, S.; Vandenabeele, P.; Dombrowicz, D.; et al. Filaggrin degradation by caspase-14 is required for UV photoprotection but does not influence allergic sensitization in a mouse model of atopic dermatitis. J. Investig. Dermatol. 2012, 132, 2857–2860. [CrossRef]
55. Scott, I.R.; Harding, C.R. Filaggrin breakdown to water binding compounds during development of the rat stratum corneum is controlled by the water activity of the environment. Dev. Biol. 1986, 115, 84–92. [CrossRef]
56. Akiyama, K.; Senshu, T. Dynamic aspects of protein deimination in developing mouse epidermis. Exp. Dermatol. 1999, 8, 177–186. [CrossRef]
57. Cau, L.; Pendaries, V.; Lhuillier, E.; Thompson, P.R.; Serre, G.; Takahara, H.; Méchin, M.C.; Simon, M. Lowering relative humidity level increases epidermal protein deimination and drives human filaggrin breakdown. J. Dermatol. Sci. 2017, 86, 106–113. [CrossRef]
58. McAleer, M.A.; Jakasa, I.; Raj, N.; O’Donnell, C.P.F.; Lane, M.E.; Rawlings, A.V.; Voegeli, R.; McLean, W.H.I.; Kezic, S.; Irvine, A.D. Early-life regional and temporal variation in filaggrin-derived natural moisturizing factor, filaggrin-processing enzyme activity, corneocyte phenotypes and plasmatic activity: Implications for atopic dermatitis. Br. J. Dermatol. 2018, 179, 431–441. [CrossRef]
59. Harding, C.R.; Scott, I.R. Histidine-rich proteins (filaggrins): Structural and functional heterogeneity during epidermal differentiation. J. Mol. Biol. 1983, 170, 651–673. [CrossRef]
60. Thyssen, J.P.; Jakasa, I.; Riethmüller, C.; Schön, M.P.; Braun, A.; Haftek, M.; Fallon, P.G.; Wróblewski, J.; Jakubowsk, H.; Eckhart, L.; et al. Filaggrin Expression and Processing Deficiencies Impair Corneocyte Surface Texture and Stiffness in Mice. J. Investig. Dermatol. 2020, 140, 615–623.e5. [CrossRef]
61. Sybert, V.P.; Dale, B.A.; Holbrook, K.A. Ichthyosis vulgaris: Identification of a defect in synthesis of filaggrin correlated with an absence of keratohyaline granules. J. Investig. Dermatol. 1985, 84, 191–194. [CrossRef]
62. Smith, F.J.; Irvine, A.D.; Terron-Kwiatkowski, A.; Sandilands, A.; Campbell, L.E.; Zhao, Y.; Liao, H.; Evans, A.T.; Goudie, D.R.; Lewis-Jones, S.; et al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat. Genet. 2006, 38, 337–342. [CrossRef]
63. Palmer, C.N.; Irvine, A.D.; Terron-Kwiatkowski, A.; Zhao, Y.; Liao, H.; Lee, S.P.; Goudie, D.R.; Sandilands, A.; Campbell, L.E.; Smith, F.J.; et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat. Genet. 2006, 38, 441–446. [CrossRef]
64. Seguchi, T.; Cui, C.Y.; Kusuda, S.; Takahashi, M.; Aisu, K.; Tezuka, T. Decreased expression of filaggrin in atopic skin. Arch. Dermatol. Res. 1996, 288, 442–446. [CrossRef]
65. Pellerin, L.; Henry, J.; Hsu, C.Y.; Balica, S.; Jean-Decoster, C.; Méchin, M.C.; Hansmann, B.; Rodriguez, E.; Weindinger, S.; Schmitt, A.M.; et al. Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin. J. Allergy Clin. Immunol. 2013, 131, 1094–1102. [CrossRef]
66. Czarnowicki, T.; He, H.; Krueger, J.G.; Gutman-Yassky, E. Atopic dermatitis endotypes and implications for targeted therapeutics. J. Allergy Clin. Immunol. 2019, 143, 1–11. [CrossRef]
67. Nettis, E.; Ortoncelli, M.; Pellacani, G.; Foti, C.; Di Leo, E.; Patruno, C.; Rongioletti, F.; Argenziano, G.; Ferrucci, S.M.; Macchia, L.; et al. A Multicenter Study on the Prevalence of Clinical Patterns and Clinical Phenotypes in Adult Atopic Dermatitis. J. Investig. Dermatol. 2020, 30, 448–450. [CrossRef]
68. Morelli, P.; Gaspari, M.; Gabriele, C.; Dastoli, S.; Bennardo, L.; Pavel, A.B.; Patruno, C.; Del Duca, E.; Nisticò, P.S. Proteomic analysis from skin swabs reveals a new set of proteins identifying skin impairment in atopic dermatitis. Exp. Dermatol. 2021, 30, 811–819. [CrossRef] [PubMed]
69. Deckers, I.A.; McLean, S.; Linssen, S.; Mommers, M.; van Schayck, C.P.; Sheikh, A. Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: A systematic review of epidemiological studies. PLoS ONE 2012, 7, e39803. [CrossRef] [PubMed]
70. Mathiesen, S.M.; Thomsen, S.F. The prevalence of atopic dermatitis in adults: Systematic review on population studies. Dermatol. Online J. 2019, 25. [CrossRef]
71. Nomura, T.; Kabashima, K. Advances in atopic dermatitis in 2019-2020: Endotypes from skin barrier, ethnicity, properties of antigen, cytokine profiles, microbiome, and engagement of immune cells. J. Allergy Clin. Immunol. 2021, 148, 1451–1462. [CrossRef]
72. Esaki, H.; Brunner, P.M.; Renert-Yuval, Y.; Czarnowicki, T.; Huynh, T.; Tran, G.; Lyon, S.; Rodriguez, G.; Immaneni, S.; Johnson, D.B.; et al. Early-onset pediatric atopic dermatitis is T(H)2 but also T(H)17 polarized in skin. J. Allergy Clin. Immunol. 2016, 138, 1639–1651. [CrossRef]
73. Renert-Yuval, Y.; Del Duca, E.; Pavel, A.B.; Fang, M.; Lefferdink, R.; Wu, J.; Diaz, A.; Estrada, Y.D.; Canter, T.; Zhang, N.; et al. The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults. J. Allergy Clin. Immunol. 2021, 148, 148–163. [CrossRef]
74. He, H.; Del Duca, E.; Diaz, A.; Kim, H.J.; Gay-Mimbrea, J.; Zhang, N.; Wu, J.; Beaziz, J.; Estrada, Y.; Krueger, J.G.; et al. Mild atopic dermatitis lacks systemic inflammation and shows reduced nonlesional skin abnormalities. J. Allergy Clin. Immunol. 2021, 147, 1369–1380. [CrossRef]
75. Scott, I.R.; Harding, C.R.; Barrett, J.G. Histidine-rich protein of the keratohyalin granules. Source of the free amino acids, urocanic acid and pyrroline-2-carboxylic acid in the stratum corneum. Biochim. Biophys. Acta 1982, 719, 110–117. [CrossRef]
76. Sandilands, A.; O’Regan, G.M.; Liao, H.; Zhao, Y.; Terron-Kwiatkowski, A.; Watson, R.M.; Cassidy, A.J.; Goudie, D.R.; Smith, F.J.; McLean, W.H.; et al. Prevalent and rare mutations in the gene encoding filaggrin cause ichthyosis vulgaris and predispose individuals to atopic dermatitis. J. Investig. Dermatol. 2006, 126, 1770–1775. [CrossRef]
77. Weidinger, S.; Illig, T.; Baurecht, H.; Irvine, A.D.; Rodriguez, E.; Diaz-Lacava, A.; Klopp, N.; Wagenpfeil, S.; Zhao, Y.; Liao, H.; et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. *J. Allergy Clin. Immunol.* **2006**, *118*, 214–219. [CrossRef]

78. Marenholz, I.; Nickel, R.; Rüschendorf, F.; Schulz, F.; Esparza-Gordillo, J.; Kerscher, T.; Grüber, C.; Lau, S.; Worm, M.; Keil, T.; et al. Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march. *J. Allergy Clin. Immunol.* **2006**, *118*, 866–871. [CrossRef]

79. Ruether, A.; Stoll, M.; Schwarz, T.; Schreiber, S.; Fölster-Holst, R. Filaggrin loss-of-function variant contributes to atopic dermatitis risk in the population of Northern Germany. *Br. J. Dermatol.* **2006**, *155*, 1093–1094. [CrossRef]

80. Nomura, T.; Sandilands, A.; Akiyama, M.; Liao, H.; Evans, A.T.; Sakai, K.; Ota, M.; Sugitura, H.; Yamamoto, K.; Sato, H.; et al. Unique mutations in the filaggrin gene in Japanese patients with ichthyosis vulgaris and atopic dermatitis. *J. Allergy Clin. Immunol.* **2007**, *119*, 434–440. [CrossRef]

81. Sandilands, A.; Terron-Kwiatkowski, A.; Hull, P.R.; O’Regan, G.M.; Clayton, T.H.; Watson, R.M.; Carrick, T.; Evans, A.T.; Liao, H.; Zhao, Y.; et al. Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. *Nat. Genet.* **2007**, *39*, 650–654. [CrossRef]

82. Baurecht, H.; Irvine, A.D.; Novak, N.; Illig, T.; Bühler, B.; Ring, J.; Wagenpfeil, S.; Weidinger, S. Toward a major risk factor for atopic eczema: Meta-analysis of filaggrin polymorphism data. *J. Allergy Clin. Immunol.* **2007**, *120*, 1406–1412. [CrossRef]

83. Ekelund, E.; Liedén, A.; Link, J.; Lee, S.P.; D’Amato, M.; Palmer, C.N.; Kockum, I.; Bradley, M. Loss-of-function variants of the filaggrin gene are associated with atopic eczema and associated phenotypes in Swedish families. *Acta Derm. Venereol.* **2008**, *88*, 15–19. [CrossRef]

84. Sasaki, T.; Kudoh, J.; Ebihara, T.; Shiohama, A.; Asakawa, S.; Shimizu, A.; Takayanagi, A.; Dekio, I.; Sadahira, C.; Amagai, M.; et al. Filaggrin loss-of-function mutations in the Japanese population. *J. Invest. Dermatol.* **2011**, *130*, 912–917. [CrossRef] [PubMed]

85. Komorowski, J.; Krzych-Fałta, E.; et al. Filaggrin gene defects are independent risk factors for atopic asthma in a Polish epidemiological study of 792 school children. *Br. J. Dermatol.* **2010**, *162*, 225–227. [CrossRef]

86. Greisenegger, E.; Novak, N.; Maintz, L.; Bieber, T.; Zimprich, F.; Haubenberger, D.; Gleiss, A.; Stingl, G.; Kopp, T.; Zimprich, A. Analysis of four prevalent filaggrin mutations (R501X, 2282del4, R2447X and S3247X) in Austrian and German patients with atopic dermatitis and asthma in the Early Treatment of the Atopic Child (ETAC) population. *Pediatr. Allergy Immunol.* **2009**, *20*, 358–361. [CrossRef]

87. Ponińska, J.; Samoliński, B.; Tomaszewska, A.; Raciborski, F.; Samel-Kowalik, P.; Walkiewicz, A.; Lipiec, A.; Piekarska, B.; Komorowski, J.; Krzych-Falta, E.; et al. Filaggrin gene defects are independent risk factors for atopic asthma in a Polish population: A study in ECAP cohort. *PLoS ONE* **2011**, *6*, e16933. [CrossRef] [PubMed]

88. Ching, G.K.; Hon, K.L.; Ng, P.C.; Leung, T.F. Filaggrin null mutations in childhood atopic dermatitis among the Chinese. *Int J. Immunogenet.* **2009**, *36*, 251–254. [CrossRef]

89. Brown, S.J.; Relton, C.L.; Liao, H.; Zhao, Y.; Sandilands, A.; McLean, W.H.; Cordell, H.J.; Reynolds, N.J. Filaggrin haploinsufficiency is highly penetrant and is associated with increased severity of eczema: Further delineation of the skin phenotype in a prospective epidemiological study of 792 school children. *Br. J. Dermatol.* **2009**, *161*, 884–889. [CrossRef]

90. Ma, L.; Zhang, L.; Di, Z.H.; Zhao, L.P.; Lu, Y.N.; Xu, J.; Chen, H.D.; Gao, X.H. Association analysis of filaggrin gene mutations and atopic dermatitis in Northern China. *Br. J. Dermatol.* **2010**, *162*, 225–227. [CrossRef]

91. Chen, H.; Common, J.E.; Haines, R.L.; Balakrishnan, A.; Brown, S.J.; Goh, C.S.; Cordell, H.J.; Sandilands, A.; Campbell, L.E.; Kroboth, K.; et al. Wide spectrum of filaggrin-null mutations in atopic dermatitis highlights differences between Singaporean Chinese and European populations. *Br. J. Dermatol.* **2011**, *165*, 106–114. [CrossRef] [PubMed]

92. Margolis, D.J.; Apter, A.J.; Gupta, J.; Hoffstad, O.; Papadopoulos, M.; Campbell, L.E.; Sandilands, A.; McLean, W.H.; Rebeck, T.R.; Mitra, N. The persistence of atopic dermatitis and filaggrin (FLG) mutations in a US longitudinal cohort. *J. Allergy Clin. Immunol.* **2012**, *130*, 912–917. [CrossRef] [PubMed]

93. Mohiuddin, M.S.; Ramamoorthy, P.; Reynolds, P.R.; Curran-Everett, D.; Leung, D.Y. Increased compound heterozygous filaggrin mutations in severe atopic dermatitis in the United States. *J. Allergy Clin. Immunol. Pract.* **2013**, *1*, 534–536. [CrossRef]

94. Mohiuddin, M.S.; Apte, J.; Gupta, J.; Hoffstad, O.; Papadopoulos, M.; Rebeck, T.R.; Widodo, R.; Mitra, N. Exome sequencing of filaggrin and related genes in African-American children with atopic dermatitis. *J. Invest. Dermatol.* **2014**, *134*, 2272–2274. [CrossRef]

95. Pocchiari, I.; Becker, L.; Stein, S.L.; Smith, M.S.; Paller, A.S. Filaggrin gene mutations in African Americans with both ichthyosis vulgaris and atopic dermatitis. *Pediatr. Dermatol.* **2014**, *31*, 489–492. [CrossRef]

96. Sasaki, T.; Furusyo, N.; Shiohama, A.; Takeuchi, S.; Nakahara, T.; Uchi, H.; Hirota, T.; Tani, M.; Shimizu, N.; Ebihara, T.; et al. Filaggrin loss-of-function mutations are not a predisposing factor for atopic dermatitis in an Ishigaki Island under subtropical climate. *J. Dermatol. Sci.* **2014**, *74*, 10–15. [CrossRef] [PubMed]

97. Komova, E.G.; Shintyapina, A.B.; Makarova, S.I.; Ivanov, M.K.; Chekryga, E.A.; Kaznacheeva, L.F.; Vavilin, V.A. Filaggrin mutations in a Western Siberian population and their association with atopic dermatitis in children. *Genet. Test. Mol. Biomark.* **2014**, *18*, 791–796. [CrossRef]
99. Park, J.; Jekarl, D.W.; Kim, Y.; Kim, J.; Kim, M.; Park, Y.M. Novel FLG null mutations in Korean patients with atopic dermatitis and comparison of the mutational spectra in Asian populations. *J. Dermatol.* 2015, 42, 867–873. [CrossRef]

100. Trisnowati, N.; Soebono, H.; Sadewa, A.H.; Kunisada, M.; Yogiarti, F.; Nishigori, C. A novel filaggrin gene mutation 7487delC in an Indonesian (Javanese) patient with atopic dermatitis. *Int. J. Dermatol.* 2016, 55, 695–697. [CrossRef]

101. Margolis, D.J.; Mitra, N.; Wubbenhorst, B.; D’Andrea, K.; Kraya, A.A.; Hoffstad, O.; Shah, S.; Nathanson, K.L. Association of Filaggrin Loss-of-Function Variants With Race in Children With Atopic Dermatitis. *JAMA Dermatol.* 2019, 155, 1269–1276. [CrossRef]

102. Gonzalez-Tarrancón, R.; Sanmartín, R.; Lorente, F.; Salvador-Rupérez, E.; Hernández-Martín, A.; Rello, L.; Puzo, J.; Gilaberte, Y. Prevalence of FLG loss-of-function mutations R501X, 2282del4, and R2447X in Spanish children with atopic dermatitis. *Pediatr. Dermatol.* 2020, 37, 98–102. [CrossRef]

103. Brown, S.J.; Sandilands, A.; Zhao, Y.; Liao, H.; Relton, C.L.; Meggitt, S.J.; Trembath, R.C.; Barker, J.N.; Reynolds, N.J.; Cordell, H.J.; et al. Prevalent and low-frequency null mutations in the filaggrin gene are associated with early-onset and persistent atopic eczema. *J. Investig. Dermatol.* 2008, 128, 1591–1594. [CrossRef]

104. Brown, S.J.; Relton, C.L.; Liao, H.; Zhao, Y.; Sandilands, A.; Wilson, I.J.; Burn, J.; Reynolds, N.J.; McLean, W.H.; Cordell, H.J. Filaggrin null mutations and childhood atopic eczema: A population-based case-control study. *J. Allergy Clin. Immunol.* 2008, 121, 940–946. [CrossRef]

105. Gruber, R.; Janecke, A.R.; Grabher, D.; Horak, E.; Schmutz, M.; Lercher, P. Lower prevalence of common filaggrin mutations in a community sample of atopic eczema: Is disease severity important? *Wien. Klin. Wochenschr.* 2010, 122, 551–557. [CrossRef]

106. Morar, N.; Cookson, W.O.; Harper, J.I.; Moffatt, M.F. Filaggrin mutations in children with severe atopic dermatitis. *J. Investig. Dermatol.* 2007, 127, 1667–1672. [CrossRef]

107. Henderson, J.; Northstone, K.; Lee, S.P.; Liao, H.; Zhao, Y.; Pembrey, M.; Mukhopadhyay, S.; Smith, G.D.; Palmer, C.N.; McLean, W.H.; et al. The burden of disease associated with filaggrin mutations: A population-based, longitudinal birth cohort study. *J. Allergy Clin. Immunol.* 2008, 121, 872–877. [CrossRef]

108. Thyssen, J.P.; Carlsen, B.C.; Bisgaard, H.; Gwercman, C.; Johansen, J.D.; Linneberg, A.; Meldgaard, M.; Szecsi, P.B.; Stender, S.; Menné, T. Individuals who are homozygous for the 2282del4 and R501X filaggrin null mutations do not always develop dermatitis and complete long-term remission is possible. *J. Eur. Acad. Dermatol. Venereol.* 2012, 26, 386–389. [CrossRef]

109. Giardina, E.; Paolillo, N.; Sinibaldi, C.; Novelli, G. R501X and 2282del4 filaggrin null mutations do not confer susceptibility to psoriasis and atopic dermatitis in Italian patients. *Dermatology* 2008, 216, 83–84. [CrossRef]

110. Cascella, R.; Foti Cuzzola, V.; Lepre, T.; Galli, E.; Moschese, V.; Chini, L.; Mazzanti, C.; Fortugno, P.; Novelli, G.; Giardina, E. Full sequencing of the FLG gene in Italian patients with atopic eczema: Evidence of new mutations, but lack of an association. *J. Investig. Dermatol.* 2011, 131, 982–984. [CrossRef]

111. Nomura, T.; Akiyama, M.; Sandilands, A.; Nemoto-Hasebe, I.; Sakai, K.; Nagasaki, A.; Ota, M.; Hata, H.; Evans, A.T.; Palmer, C.N.; et al. Specific filaggrin mutations cause ichthyosis vulgaris and are significantly associated with atopic dermatitis in Japan. *J. Investig. Dermatol.* 2008, 128, 1436–1441. [CrossRef]

112. Brown, S.J.; Kroboth, K.; Sandilands, A.; Campbell, L.E.; Pohler, E.; Kezic, S.; Cordell, H.J.; McLean, W.H.; Irvine, A.D. Intragenic copy number variation within filaggrin contributes to the risk of atopic dermatitis with a dose-dependent effect. *J. Investig. Dermatol.* 2012, 132, 98–104. [CrossRef]

113. Barker, J.N.; Palmer, C.N.; Zhao, Y.; Liao, H.; Hull, P.R.; Lee, S.P.; Allen, M.H.; Meggitt, S.J.; Reynolds, N.J.; Trembath, R.C.; et al. Null mutations in the filaggrin gene (FLG) determine major susceptibility to early-onset atopic dermatitis that persists into adulthood. *J. Investig. Dermatol.* 2007, 127, 564–567. [CrossRef]

114. Rice, N.E.; Patel, B.D.; Lang, I.A.; Kumari, M.; Frayling, T.M.; Murray, A.; Melzer, D. Filaggrin gene mutations are associated with asthma and eczema in later life. *J. Allergy Clin. Immunol.* 2008, 122, 834–836. [CrossRef]

115. Tokura, Y.; Hayano, S. Subtypes of atopic dermatitis: From phenotype to endotype. *Allergol. Int.* 2021. [CrossRef]

116. Howell, M.D.; Kim, B.E.; Gao, P.; Grant, A.V.; Boguniewicz, M.; Debenedetto, A.; Schneider, L.; Beck, L.A.; Barnes, K.C.; Leung, D.Y. Cytokine modulation of atopic dermatitis filaggrin skin expression. *J. Allergy Clin. Immunol.* 2007, 120, 150–155. [CrossRef] [PubMed]

117. Zaniboni, M.C.; Samorano, L.P.; Orfali, R.L.; Aoki, V. Skin barrier in atopic dermatitis: Beyond filaggrin. *An. Bras. Dermatol.* 2016, 91, 472–478. [CrossRef] [PubMed]

118. Dajnoki, Z.; Beke, G.; Mócsai, G.; Kapitány, A.; Gáspár, K.; Hajdu, K.; Emri, G.; Nagy, B.; Kovács, I.; Beke, L.; et al. Immune-mediated Skin Inflammation is Similar in Severe Atopic Dermatitis Patients With or Without Filaggrin Mutations. *Acta Derm. Venerol.* 2016, 96, 645–650. [CrossRef]

119. Gittler, J.K.; Shemer, A.; Suárez-Fariñas, M.; Fuentes-Duculan, J.; Gulewicz, K.J.; Wang, C.Q.; Mitsui, H.; Cardinale, I.; de Guzman Strong, C.; Krueger, J.G.; et al. Progressive activation of TH1/TH2 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. *J. Investig. Clin. Immunol.* 2012, 130, 1344–1354. [CrossRef] [PubMed]

120. Hvid, M.; Johansen, C.; Deleuran, B.; Kemp, K.; Deleuran, M.; Vestergaard, C. Regulation of caspase 14 expression in keratinocytes by inflammatory cytokines—a possible link between reduced skin barrier function and inflammation? *Exp. Dermatol.* 2011, 20, 633–636. [CrossRef]
Gutowska-Owsiak, D.; de La Serna, J.B.; Fritzsche, M.; Naeem, A.; Podobas, E.I.; Leeming, M.; Colin-York, H.; O'Shaughnessy, S.P.; Abdul-Ghaffar, S.; Weller, R.B.; Brown, S.B. Protease-antiprotease imbalance may be linked to potential defects in filaggrin expression in human organotypic skin models. J. Allergy Clin. Immunol. 2012, 129, 426–433.

Okamoto, R.; Arikawa, J.; Ishibashi, M.; Kawashima, M.; Takagi, Y.; Imokawa, G. Sphingosylphosphorylcholine is upregulated in atopic dermatitis patients. J. Allergy Clin. Immunol. 2010, 126, 9–16.

Gutowska-Owsiak, D.; Schaupp, A.L.; Salimi, M.; Taylor, S.; Ogg, G.S. Interleukin-22 downregulates filaggrin expression and affects expression of profilaggrin processing enzymes. Br. J. Dermatol. 2015, 172, 762–769.

Ziyab, A.H.; Karmaus, W.; Holloway, J.W.; Zhang, H.; Ewart, S.; Arshad, S.H. DNA methylation of the filaggrin gene adds to the risk of eczema associated with loss-of-function variants. J. Eur. Acad. Dermatol. Venereol. 2013, 27, e420–e423.

Kim, J.H.; Bae, H.C.; Ko, N.Y.; Lee, S.H.; Jeong, S.H.; Lee, H.; Ryu, W.J.; Kye, Y.C.; Son, S.W. Thymic stromal lymphopoietin downregulates filaggrin expression by signal transducer and activator of transcription 3 (STAT3) and extracellular signal-regulated kinase (ERK) phosphorylation in keratinocytes. J. Allergy Clin. Immunol. 2015, 136, 205–208. [CrossRef]

van Drongelen, V.; Haisma, E.M.; Out-Luiting, J.J.; Nibbering, P.H.; El Ghalbzouri, A. Reduced filaggrin expression is accompanied by increased Staphylococcus aureus colonization of epidermal skin models. Clin. Exp. Allergy 2014, 44, 1515–1524. [CrossRef]

Seltmann, J.; Roessen, L.M.; von Hesler, F.W.; Wittmann, M.; Werfel, T. IL-33 impacts on the skin barrier by downregulating the expression of filaggrin. J. Allergy Clin. Immunol. 2015, 135, 1659–1661. [CrossRef]

Vakirlis, E.; Lazaridou, E.; Tzellos, T.G.; Gerou, S.; Chatzidimitriou, D.; Ioannides, D. Investigation of cytokine levels and their association with SCORAD index in adults with acute atopic dermatitis. J. Eur. Acad. Dermatol. Venereol. 2011, 25, 409–416. [CrossRef]

Portugal-Cohen, M.; Horev, L.; Ruffer, C.; Schlippe, G.; Voss, W.; Ma’or, Z.; Oron, M.; Soroka, Y.; Frušić-Zlotkin, M.; Milner, Y.; et al. Non-invasive skin biomarkers quantification of psoriasis and atopic dermatitis: Cytokines, antioxidants and psoriatic skin auto-fluorescence. Biomed. Pharmacother. 2012, 66, 293–299. [CrossRef]

Bitton, A.; Avlas, S.; Reichman, H.; Itan, M.; Karo-Atar, D.; Azouz, N.P.; Rozenberg, P.; Diesendruck, Y.; Nahary, L.; Rothenberg, M.E.; et al. A key role for IL-13 signaling via the type 2 IL-4 receptor in experimental atopic dermatitis. Sci. Immunol. 2020, 5, eabb1667. [CrossRef]

Móbus, I.; Rodriguez, E.; Harder, I.; Stödl, D.; Boraczynski, N.; Gerdes, S.; Kleinheinz, A.; Abraham, S.; Heratizadeh, A.; Handrick, C.; et al. Atopic dermatitis displays stable and dynamic skin transcriptome signatures. J. Allergy Clin. Immunol. 2021, 147, 213–223. [CrossRef]

Guttman-Yassky, E.; Bissonnette, R.; Ungar, B.; Suárez-Fariñas, M.; Ardeleanu, M.; Esaki, H.; Suprun, M.; Estrada, Y.; Xu, H.; Peng, X.; et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J. Allergy Clin. Immunol. 2019, 143, 155–172. [CrossRef]

Okamoto, R.; Arikawa, J.; Ishibashi, M.; Kawashima, M.; Takagi, Y.; Imokawa, G. Sphingosylphosphorylcholine is upregulated in the stratum corneum of patients with atopic dermatitis. J. Lipid. Res. 2003, 44, 93–102. [CrossRef]

Choi, H.; Kim, S.; Kim, H.J.; Kim, K.M.; Lee, C.H.; Shin, J.H.; Noh, M. Sphingosylphosphorylcholine down-regulates filaggrin gene transcription through NOX5-based NADPH oxidase and cyclooxygenase-2 in human keratinocytes. Biochem. Pharmacol. 2010, 80, 95–103. [CrossRef]

Ming, M.; Zhao, B.; Sheh, C.R.; Shah, P.; Qiang, L.; White, S.R.; Sims, D.M.; He, Y.Y. Loss of sirtuin 1 (SIRT1) disrupts skin barrier integrity and sensitizes mice to epicutaneous allergen challenge. J. Allergy Clin. Immunol. 2015, 135, 936–945. [CrossRef]

Gutowska-Owsiak, D.; de La Serna, J.B.; Fritzsche, M.; Voss, W.; Ma’or, Z.; Oron, M.; Soroka, Y.; Frušić-Zlotkin, M.; Milner, Y.; et al. Non-invasive skin biomarkers quantification of psoriasis and atopic dermatitis: Cytokines, antioxidants and psoriatic skin auto-fluorescence. Biomed. Pharmacother. 2012, 66, 293–299. [CrossRef]

Handrick, C.; et al. Atopic dermatitis displays stable and dynamic skin transcriptome signatures. J. Allergy Clin. Immunol. 2021, 147, 213–223. [CrossRef]

Kim, J.H.; Bae, H.C.; Ko, N.Y.; Lee, S.H.; Jeong, S.H.; Lee, H.; Ryu, W.J.; Kye, Y.C.; Son, S.W. Thymic stromal lymphopoietin downregulates filaggrin expression by signal transducer and activator of transcription 3 (STAT3) and extracellular signal-regulated kinase (ERK) phosphorylation in keratinocytes. J. Allergy Clin. Immunol. 2015, 136, 205–208. [CrossRef]
143. Ding, X.; Willenborg, S.; Bloch, W.; Wickström, S.A.; Wagle, P.; Brodesser, S.; Roers, A.; Jais, A.; Brüning, J.C.; Hall, M.N.; et al. Epidermal mammalian target of rapamycin complex 2 controls lipid synthesis and filaggrin processing in epidermal barrier formation. J. Allergy Clin. Immunol. 2020, 145, 283–300.e8. [CrossRef] [PubMed]

144. Mercurio, L.; Albanesi, C.; Madonna, S. Recent Updates on the Involvement of PI3K/AKT/mTOR Molecular Cascade in the Pathogenesis of Hyperproliferative Skin Disorders. Front. Med. 2021, 8, 665647. [CrossRef]

145. Fanton, N.; Santoro, D.; Cornegliani, L.; Marsella, R. Increased filaggrin-metabolizing enzyme activity in atopic skin: A pilot study using a canine model of atopic dermatitis. Vet. Dermatol. 2017, 28, 479–e111. [CrossRef]

146. Di, Z.H.; Ma, L.; Qi, R.Q.; Sun, X.D.; Huo, W.; Zhang, L.; Lyu, Y.N.; Hong, Y.X.; Chen, H.D.; Gao, X.H. T Helper 1 and T Helper 2 Cytokines Differentially Modulate Expression of Filaggrin and its Processing Proteases in Human Keratinocytes. Chin. Med. J. 2016, 129, 295–303. [CrossRef]

147. Yamamoto, M.; Kamata, Y.; Iida, T.; Fukushima, H.; Nomura, J.; Saito, M.; Tajima, M.; Okubo, Y.; Momoi, T.; Tsuboi, R.; et al. Quantification of activated and total caspase-14 with newly developed ELISA systems in normal and atopic skin. J. Dermatol. Sci. 2011, 61, 110–117. [CrossRef]

148. Klapan, K.; Frangež, Ž.; Markov, N.; Yousefi, S.; Simon, D.; Simon, H.U. Evidence for Lysosomal Dysfunction within the Epidermis in Psoriasis and Atopic Dermatitis. J. Investig. Dermatol. 2021, 141, 2838–2848. [CrossRef]

149. Scharschmidt, T.C.; Man, M.Q.; Hatano, Y.; Crumrine, D.; Gunathilake, R.; Sundberg, J.P.; Silva, K.A.; Mauro, T.M.; Hupe, M.; Cho, S.; et al. Filaggrin deficiency confers a paracellullar barrier abnormality that reduces inflammatory thresholds to irritants and haptens. J. Allergy Clin. Immunol. 2009, 124, 496–506.e1–6. [CrossRef]

150. Fallou, P.G.; Sasaki, T.; Sandilands, A.; Campbell, L.E.; Saunders, S.P.; Mangan, N.E.; Callanan, J.J.; Kawasaki, H.; Shiohama, A.; Kubo, A.; et al. A homozygous frameshift mutation in the mouse Flg gene facilitates enhanced percutaneous allergen priming. Nat. Genet. 2009, 41, 602–608. [CrossRef]

151. Oyoshi, M.K.; Murphy, G.F.; Geha, R.S. Filaggrin-deficient mice exhibit TH17-dominated skin inflammation and permissiveness to epicutaneous sensitization with protein antigen. J. Allergy Clin. Immunol. 2009, 124, 485–493.e1. [CrossRef]

152. Blunder, S.; Rühl, R.; Moosbrugger-Martinez, V.; Krimmel, C.; Geisler, A.; Zhu, H.; Crumrine, D.; Elias, P.M.; Gruber, R.; Schmuth, M.; et al. Alterations in Epidermal Eicosanoid Metabolism Contribute to Inflammation and Impaired Late Differentiation in FLG-Mutated Atopic Dermatitis. J. Investig. Dermatol. 2017, 137, 706–715. [CrossRef]

153. Elias, M.S.; Long, H.A.; Newm, C.F.; Wilson, P.A.; West, A.; McGill, P.J.; Wu, K.C.; Donaldson, M.J.; Reynolds, N.J. Proteomic analysis of filaggrin deficiency identifies molecular signatures characteristic of atopic eczema. J. Allergy Clin. Immunol. 2017, 140, 1299–1309. [CrossRef]

154. Wang, X.W.; Wang, J.J.; Gutowska-Owsiak, D.; Salimi, M.; Selvakumar, T.A.; Gwela, A.; Chen, L.Y.; Wang, Y.J.; Giannoulatou, E.; Ogg, G. Deficiency of filaggrin regulates endogenous cysteine protease activity, leading to impaired skin barrier function. Clin. Exp. Dermatol. 2017, 42, 622–631. [CrossRef]

155. Igawa, S.; Kishibe, M.; Minami-Hori, M.; Honma, M.; Tsujimura, H.; Ishikawa, J.; Fujimura, T.; Murakami, M.; Ishida-Yamamoto, A. Incomplete KLK7 Secretion and Upregulated LEKTI Expression Underlie Hyperkeratotic Stratum Corneum in Atopic Dermatitis. J. Investig. Dermatol. 2017, 137, 449–456. [CrossRef]

156. Jakasa, I.; Koster, E.S.; Calkoen, F.; McLean, W.H.; Campbell, L.E.; Bos, J.D.; Verberk, M.M.; Kezic, S. Skin barrier function in healthy subjects and patients with atopic dermatitis in relation to filaggrin loss-of-function mutations. J. Investig. Dermatol. 2011, 131, 540–542. [CrossRef]

157. van Drongelen, V.; Alloul-Ramdhani, M.; Danso, M.O.; Mieremet, A.; Mulder, A.; van Smeden, J.; Bouwstra, J.A.; El Ghallbouri, A. Knock-down of filaggrin does not affect lipid organization and composition in stratum corneum of reconstructed human skin equivalents. Exp. Dermatol. 2013, 22, 807–812. [CrossRef]

158. van den Bogaard, E.; Ilic, D.; Dubrac, S.; Tomic-Canic, M.; Bouwstra, J.; Celli, A.; Mauro, T. Perspective and Consensus Opinion: Good Practices for Using Organotypic Skin and Epidermal Equivalents in Experimental Dermatology Research. J. Investig. Dermatol. 2021, 141, 203–205. [CrossRef]

159. van Drongelen, V.; Alloul-Ramdhani, M.; Danso, M.O.; Mieremet, A.; Mulder, A.; van Smeden, J.; Bouwstra, J.A.; El Ghallbouri, A. Knock-down of filaggrin does not affect lipid organization and composition in stratum corneum of reconstructed human skin equivalents. Exp. Dermatol. 2013, 22, 807–812. [CrossRef]

160. van den Boogaard, E.; Ilic, D.; Dubrac, S.; Tomic-Canic, M.; Bouwstra, J.; Celli, A.; Mauro, T. Perspective and Consensus Opinion: Good Practices for Using Organotypic Skin and Epidermal Equivalents in Experimental Dermatology Research. J. Investig. Dermatol. 2021, 141, 203–205. [CrossRef]

161. Jung, T.; Stingl, G. Atopic dermatitis: Therapeutic concepts evolving from new pathophysiologic insights. J. Allergy Clin. Immunol. 2008, 122, 1074–1081. [CrossRef]
165. Smieszek, S.P.; Welsh, S.; Xiao, C.; Wang, J.; Polymeropoulos, C.; Birznieks, G.; Polymeropoulos, M.H. Correlation of age-of-onset of Atopic Dermatitis with Filaggrin loss-of-function variant status. *Sci. Rep.* 2020, 10, 2721. [CrossRef]

166. Nemoto-Haseibe, I.; Akiyama, M.; Nomura, T.; Sandilands, A.; McLean, W.H.; Shimizu, H. Clinical severity correlates with impaired barrier in filaggrin-related eczema. *J. Investig. Dermatol.* 2009, 129, 682–689. [CrossRef]

167. Jungersted, J.M.; Scheer, H.; Mempel, M.; Baurecht, H.; Cifuentes, L.; Högh, J.K.; Høllgren, L.I.; Jemec, G.B.; Agner, T.; Weidinger, S. Stratum corneum lipids, skin barrier function and filaggrin mutations in patients with atopic eczema. *Allergy* 2010, 65, 911–918. [CrossRef]

168. O’Regan, G.M.; Kemperman, P.M.; Sandilands, A.; Chen, H.; Campbell, L.E.; Kroboth, K.; Watson, R.; Rowland, M.; Puppels, G.J.; McLean, W.H.; et al. Raman profiles of the stratum corneum define 3 filaggrin genotype-determined atopic dermatitis endophenotypes. *J. Allergy Clin. Immunol.* 2010, 126, 574–580. [CrossRef] [PubMed]

169. Retraction notice. *J. Allergy Clin. Immunol.* 2021, 147, 1526. [CrossRef]

170. Perusquía-Ortíz, A.M.; Oji, V.; Sauerland, M.C.; Tarinski, T.; Zaraeva, I.; Seller, N.; Metze, D.; Aufenvenne, K.; Haussler, I.; Traupe, H. Complete filaggrin deficiency in ichthyosis vulgaris is associated with only moderate changes in epidermal permeability barrier function profile. *J. Eur. Acad. Dermatol. Venereol.* 2013, 27, 1552–1558. [CrossRef] [PubMed]

171. Bouwstra, J.A.; Ponec, M. The skin barrier in healthy and diseased state. *Biochem. Biophys. Acta* 2006, 1758, 2080–2095. [CrossRef] [PubMed]

172. Toncic, R.J.; Jakasa, I.; Hadzavdic, S.L.; Goorden, S.M.; Vlugt, K.J.G.; Stet, F.S.; Balic, A.; Petkovic, M.; Pavicic, B.; Zuzul, K.; et al. Knock-down of filaggrin influences the mitogen-activated protein kinases signaling pathway migration in filaggrin-deficient skin equivalents. *Exp. Dermatol.* 2011, 20, 137, 482–491. [CrossRef]

173. Saunders, S.P.; Goh, C.S.; Brown, S.J.; Palmer, C.N.; Porter, R.M.; Cole, C.; Campbell, L.E.; Gierlingski, M.; Barton, G.J.; Schneider, G.; et al. Tmem79/Matt is the matted mouse gene and is a predisposing gene for atopic dermatitis in human subjects. *J. Allergy Clin. Immunol.* 2013, 132, 1121–1129. [CrossRef]

174. Malik, K.; He, H.; Huynh, T.N.; Tran, G.; Mueller, K.; Doytcheva, K.; Renert-Yuval, Y.; Czarnowicki, T.; Magidi, S.; Chou, M.; et al. Ichthyosis molecular fingerprinting shows profound T(H)17 skewing and a unique barrier genomic signature. *J. Allergy Clin. Immunol.* 2019, 143, 604–618. [CrossRef]
241. Militz, V.; Latreille, J.; Gardinier, S.; Jdid, R.; Drouault, Y.; Hufnagl, P.; Eckhart, L.; Guinot, C.; Tschachler, E. Impact of filaggrin

257. Johansson, E.K.; Bergström, A.; Kull, I.; Lind, T.; Söderhäll, C.; van Hage, M.; Wahlgren, C.F. IgE sensitization in relation to preschool eczema and filaggrin mutation. J. Allergy Clin. Immunol. 2012, 129, 1153–1155. [CrossRef]

240. Ginger, R.S.; Blachford, S.; Rowland, J.; Rowson, M.; Harding, C.R. Filaggrin repeat number polymorphism is associated with a dry skin phenotype. Arch. Dermatol. Res. 2005, 297, 235–241. [CrossRef]

246. Gustafsson, D.; Sjöberg, O.; Foucard, T. Development of allergies and asthma in infants and young children with atopic dermatitis a prospective follow-up to 7 years of age. Allergy 2000, 55, 240–245. [CrossRef] [PubMed]

245. Ota, M.; Sasaki, T.; Ebihara, T.; Yokosawa, E.; Murakami, Y.; Matsunaka, H.; Chinuki, Y.; Amagai, M.; Morita, E. Filaggrin-gene loss-of-function variants predispose to the comorbidity of eczema, asthma, and rhinitis: Results from the Isle of Wight birth cohort. J. Allergy Clin. Immunol. 2008, 121, 1203–1209. [CrossRef]

243. Kezic, S.; Kammeyer, A.; Calkoen, F.; Fluhr, J.W.; Bos, J.D. Natural moisturizing factor components in the stratum corneum as biomarkers of filaggrin genotype: Evaluation of minimally invasive methods. Br. J. Dermatol. 2009, 161, 1098–1104. [CrossRef] [PubMed]

259. Elhaji, Y.; Sasseville, D.; Pratt, M.; Asai, Y.; Matheson, K.; McLean, W.H.; Hull, P.R. Filaggrin gene loss-of-function mutations constitute a factor in patients with multiple contact allergies. Contact Dermat. 2019, 80, 354–358. [CrossRef]
260. Simpson, A.; Brough, H.A.; Haider, S.; Belgrave, D.; Murray, C.S.; Custovic, A. Early-life inhalant allergen exposure, filaggrin genotype, and the development of sensitization from infancy to adolescence. *J. Allergy Clin. Immunol.* 2020, 145, 993–1001. [CrossRef]

261. Imoto, Y.; Enomoto, H.; Fujieda, S.; Okamoto, M.; Sakashita, M.; Susuki, D.; Okada, M.; Hirota, T.; Tamari, M.; Ebe, K.; et al. S2534X mutation in the filaggrin gene is associated with allergen sensitization in the Japanese population. *J. Allergy Clin. Immunol.* 2010, 12, 498–500. [CrossRef]

262. Bisgaard, H.; Simpson, A.; Palmer, C.N.; Bønnelykke, K.; McLean, I.; Mukhopadhyay, S.; Pipper, C.B.; Hallkjær, L.; Lipworth, B.; Hankinson, J.; et al. Gene-environment interaction in the onset of eczema in infancy: Filaggrin loss-of-function mutations enhanced by neonatal cat exposure. *PLoS Med.* 2008, 5, e131. [CrossRef]

263. McPherson, T.; Sherman, V.J.; Aslam, A.; Crack, L.; Chan, H.; Lloyd-Lavery, A.; Jones, L.; Ardern-Jones, M.; Ogg, G. Filaggrin null mutations associated with increased frequencies of allergen-specific CD4+ T-helper 2 cells in patients with atopic eczema. *Br. J. Dermatol.* 2010, 163, 544–549. [CrossRef]

264. Brown, S.J.; Asai, Y.; Cordell, H.J.; Campbell, L.E.; Zhao, Y.; Liao, H.; Northstone, K.; Henderson, J.; Alizadehfar, R.; Ben-Shoshan, M.; et al. Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy. *J. Allergy Clin. Immunol.* 2011, 127, 661–667. [CrossRef]

265. Li, M.; Liu, J.B.; Liu, Q.; Yao, M.; Cheng, R.; Xue, H.; Zhou, H.; Yao, Z. Interactions between FLG mutations and allergens in atopic dermatitis. *Arch. Dermatol. Res.* 2012, 304, 787–793. [CrossRef]

266. Brough, H.A.; Simpson, A.; Makinson, K.; Hankinson, J.; Brown, S.; Douiri, A.; Belgrave, D.C.; Penagos, M.; Stephens, A.C.; McLean, W.H.; et al. Peanut allergy: Effect of environmental peanut exposure in children with filaggrin loss-of-function mutations. *J. Allergy Clin. Immunol.* 2014, 134, 867–875. [CrossRef]

267. Berdysheva, E.; Goleva, E.; Bronova, I.; Bronof, A.S.; Hoffman, B.C.; Ramirez-Gama, M.A.; Garcia, S.L.; Crumrine, D.; Elias, P.M.; Cho, C.B.; et al. Unique skin abnormality in patients with peanut allergy but no atopic dermatitis. *J. Allergy Clin. Immunol.* 2021, 147, 361–367. [CrossRef]

268. Schmitt, J.; Weidinger, S. Alternative models of comorbidity: A framework for the interpretation of epidemiological association studies. *J. Investig. Dermatol.* 2014, 134, 303–307. [CrossRef]

269. Flohr, C.; Mann, J. New insights into the epidemiology of childhood atopic dermatitis. *Allergy* 2014, 69, 3–16. [CrossRef]

270. Lerbaek, A.; Bisgaard, H.; Agner, T.; Ohm Kyvik, K.; Palmer, C.N.; Menné, T. Filaggrin null alleles are not associated with hand eczema or contact allergy. *Br. J. Dermatol.* 2007, 157, 1199–1204. [CrossRef] [PubMed]

271. Brown, S.J.; Cordell, H.J. Are filaggrin mutations associated with hand eczema or contact allergy?–we do not know. *Br. J. Dermatol.* 2008, 158, 1383–1384. [CrossRef]

272. Carlsen, B.C.; Johansen, J.D.; Menné, T.; Meldgaard, M.; Szecsi, P.B.; Stender, S.; Thyssen, J.P. Filaggrin null mutations and association with contact allergy and allergic contact dermatitis: Results from a tertiary dermatology clinic. *Contact Dermat.* 2010, 63, 89–95. [CrossRef] [PubMed]

273. Hougaard, M.G.; Johansen, J.D.; Linneberg, A.; Bandier, J.; Stender, S.; Carlsen, B.C.; Szecsi, P.B.; Meldgaard, M.; Menné, T.; Thyssen, J.P. Skin prick test reactivity to aeroallergens by filaggrin mutation status. *J. Eur. Acad. Dermatol. Venereol.* 2014, 28, 238–241. [CrossRef] [PubMed]

274. Thysсен, J.P.; Tang, L.; Husemøen, L.L.; Stender, S.; Szecsi, P.B.; Menné, T.; Johansen, J.D.; Linneberg, A. Filaggrin gene mutations are not associated with food and aeroallergen sensitization without concomitant atopic dermatitis in adults. *J. Allergy Clin. Immunol.* 2015, 135, 1375–1378. [CrossRef]

275. Carlsen, B.C.; Meldgaard, M.; Hamann, D.; Hamann, Q.; Hamann, C.; Thyssen, J.P.; Meyer, D.M.; Gruninger, S.E.; Hamann, C. Latex allergy and filaggrin null mutations. *J. Dent.* 2011, 39, 128–132. [CrossRef]

276. Thyszen, J.P.; Johansen, J.D.; Zachariae, C.; Menné, T.; Linneberg, A. Xerosis is associated with atopic dermatitis, hand eczema and contact sensitization independent of filaggrin gene mutations. *Acta Derm. Venereol.* 2013, 93, 406–410. [CrossRef]

277. Novak, N.; Baurecht, H.; Schäfer, T.; Rodríguez, E.; Wagenpfeil, S.; Klopp, N.; Heinrich, J.; Behrendt, H.; Ring, J.; Wichmann, E.; et al. Loss-of-function mutations in the filaggrin gene and allergic contact sensitization to nickel. *J. Investig. Dermatol.* 2008, 128, 1430–1435. [CrossRef]

278. Thyszen, J.P.; Johansen, J.D.; Linneberg, A.; Menné, T.; Nielsen, N.H.; Meldgaard, M.; Szecsi, P.B.; Stender, S.; Carlsen, B.C. The association between null mutations in the filaggrin gene and contact sensitization to nickel and other chemicals in the general population. *Br. J. Dermatol.* 2010, 162, 1278–1285. [CrossRef]

279. Ross-Hansen, K.; Menné, T.; Johansen, J.D.; Carlsen, B.C.; Linneberg, A.; Nielsen, N.H.; Stender, S.; Meldgaard, M.; Szecsi, P.B.; Thyssen, J.P. Nickel reactivity and filaggrin null mutations—evaluation of the filaggrin bypass theory in a general population. *Contact Dermat.* 2011, 64, 24–31. [CrossRef]

280. Ross-Hansen, K.; Johansen, J.D.; Velund, A.; Menné, T.; Thyssen, J.P. The nickel dose-response relationship by filaggrin genotype (FLG). *Contact Dermat.* 2014, 71, 49–53. [CrossRef]

281. Petersen, T.H.; Jee, M.H.; Gadsbell, A.; Schmidt, J.D.; Sloth, J.J.; Sonnenberg, G.F.; Geisler, C.; Thyssen, J.P.; Bonefeld, C.M. Mice with epidermal filaggrin deficiency show increased immune reactivity to nickel. *Contact Dermat.* 2019, 80, 139–148. [CrossRef]

282. Ross-Hansen, K.; Østergaard, O.; Tanassi, J.T.; Thyssen, J.P.; Johansen, J.D.; Menné, T.; Heegaard, N.H.H. Filaggrin is a predominant member of the denaturation-resistant nickel-binding proteome of human epidermis. *J. Investig. Dermatol.* 2014, 134, 1164–1166. [CrossRef]
Podobas, E.I.; Gutowska-Owsiak, D.; Moretti, S.; Poznański, J.; Kulińczak, M.; Grynberg, M.; Gruca, A.; Bonna, A.; Płonka, D.; Ogg, G.; et al. Ni(2+) Assisted Hydrolysis May Affect the Human Proteome; Filaggrin Degradation Ex Vivo as an Example of Possible Consequences. *Front. Mol. Biosci.* 2022, *9*, 828674. [CrossRef]

Irvine, A.D.; McLean, W.H.; Leung, D.Y. Filaggrin mutations associated with skin and allergic diseases. *N. Engl. J. Med.* 2011, *365*, 1315–1327. [CrossRef]

Brown, S.J.; McLean, W.H. One remarkable molecule: Filaggrin. *J. Investig. Dermatol.* 2012, *132*, 751–762. [CrossRef]